# 5-(Methylthio)tetrazoles as Versatile Synthons in the Stereoselective Synthesis of Polycyclic Pyrazolines via Photoinduced Intramolecular Nitrile Imine–Alkene 1,3-Dipolar Cycloaddition

# **Supporting Information**

Daniel Pla,\*<sup>,†</sup> Derek S. Tan,\*<sup>,†,‡</sup> and David Y. Gin<sup>†,‡,§</sup>

<sup>†</sup>Molecular Pharmacology and Chemistry Program and <sup>‡</sup>Tri-Institutional Research Program, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, Box 422, New York, New York 10065, United States <sup>§</sup>Deceased March 22, 2011

# **TABLE OF CONTENTS**

A.	General Experimental Procedures, Materials and Instrumentation	S2
B.	Synthesis of 2-Alkylated Tetrazole Derivatives 2, 5, 11, 13, and 15	S3-S13
C.	Synthesis of Fused Pyrazoline and Pyrazole Derivatives $3, 4, 6 - 8, 14$ and $16$	S14-S23
D.	Isomerization Studies of Model Olefin Substrates under the Reaction Conditions	S25-S26
E.	UV Absorbance Spectra of Tetrazole Substrates	S27-S28
F.	Further Functionalization of Pyrazoline Scaffolds: Synthesis of 8, 16, 17, 18	S29-S30
G.	Total Syntheses of $(\pm)$ -Newbouldine and Withasomnine <b>19-28</b>	S31-S34
H.	NMR Data of Natural and Synthetic 19	S35
I.	NMR Data of Natural and Synthetic 20	S36
J.	Synthesis of Azetidine, Azepane and Azocane Quasidimer Structures	S37-S38
K.	References and Notes	S39-S40
L.	<sup>1</sup> H and <sup>13</sup> C-NMR Spectra	S41-S123
M.	NOESY, COSY, HSQC and HMBC Spectra of Selected Compounds	S124-S140

#### A. General Experimental Procedures, Materials and Instrumentation.

**Materials.** CH<sub>2</sub>Cl<sub>2</sub>, THF, Et<sub>2</sub>O, MeCN and toluene were purified by passage through two packed columns of neutral alumina under an argon atmosphere. Methanol was distilled from magnesium at 760 Torr. All other chemicals were obtained from commercial vendors and were used without further purification unless noted otherwise.

Instrumentation. Automated flash chromatography was performed with an Isco Combiflash medium-pressure liquid chromatograph with Redisep silica or alumina gel columns (47-60 µm). Photochemical irradiation was performed in sealed quartz tubes with a Luzchem® Photochemical reactor or with a Pen-Ray lamp. Microwave-assisted reactions were run in a Biotage microwave. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were recorded on a Bruker 500 MHz spectrometer and a Bruker 600 MHz spectrometer. Chemical shifts are reported in ppm referenced to the appropriate residual solvent peaks (CD<sub>3</sub>OD, d<sub>6</sub>-DMSO, C<sub>6</sub>D<sub>6</sub> or CDCl<sub>3</sub>) and coupling constants are reported in Hz. The multiplicity of signals is indicated using the following abbreviations: s = singlet, d = doublet, t = triplet, q = quadruplet, bs = broad singlet, bd = broaddoublet, m = multiplet. Infrared (FTIR) spectra were obtained using a Bruker Tensor 27. Vibration frequencies are expressed in cm<sup>-1</sup>. High-resolution mass spectrometry (HRMS) was performed on a Waters LCT Premier XE high-resolution mass spectrometer. Melting points were determined in open glass capillaries with an Stanford Research Systems OptiMelt automated melting point system and are uncorrected. Optical rotations were determined on a JASCO P-1020 polarimeter at 589 nm using a PTC-103T temperature controller. UV spectra were recorded on an Agilent Cary 100 UV-Visible Spectrophotometer using the Cary WinUV software.

**General Experimental Procedures.** Reactions were performed in flame-dried borosilicate or quartz sealed-tubes or modified Schlenk (Kjeldahl shape) flasks fitted with a glass stopper under a positive pressure of argon, unless otherwise noted. Air- and moisture-sensitive liquids and solutions were transferred via syringe. Organic solutions were concentrated by rotary evaporation below 30 °C. Thin-layer chromatography was performed using glass plates precoated to a depth of 0.25 mm with 230-400 mesh silica gel impregnated with a fluorescent indicator (254 nm) and visualized under UV light (254 and 360 nm), or stained with I<sub>2</sub>, Ceric Ammonium Molybdate in conc.  $H_2SO_4$  or with a KMnO<sub>4</sub> solution (contains K<sub>2</sub>CO<sub>3</sub>, NaOH). Column chromatography was run using silica gel 60.

- A) General Procedure for the Alkylation of Tetrazoles using Mitsunobu Conditions. Diisopropyl azodicarboxylate (292  $\mu$ L, 1.50 mmol) was added to a stirred solution of 5-methylthio-1*H*-tetrazole (116.2 mg, 1.00 mmol, 1.0 equiv), PPh<sub>3</sub> (393.1 mg, 1.50 mmol) and the alcohol **5** (1.1 or 1.3 equiv) in THF (10 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc gave **3** in moderate to good yields (39-90%).<sup>1</sup>
- **B)** General Procedure for the Carboamination Reaction. A solution of tetrazole derivative **3** (1.0 mmol) in MeCN (3 mL) was purged with Ar. The reaction mixture was irradiated under 254 nm at r.t. for 5 h, unless otherwise stated. The organic solution was concentrated to give a crude material, which was purified by silica gel chromatography to give **2** (yield 19–96%).<sup>2</sup>

### B. Synthesis of 2-Alkylated Tetrazole Derivatives 2, 5, 11, 13, 15.



**5-(Methylthio)-2-(pent-4-enyl)-2***H***-tetrazole (2a)**. Following the general procedure **A** and starting from pent-4-en-1-ol (733 mg, 8.50 mmol, 1.3 equiv), elution with hexane/EtOAc (100:0 to 80:20) gave **2a** (1.006 g, 84%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.57 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.77 (dd, J = 17.0, 10.3 Hz, 1H), 5.11 − 5.00 (m, 2H), 4.59 (t, J = 6.9 Hz, 2H), 2.65 (s, 3H), 2.15 − 2.04 (m, 4H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>) δ 164.8, 136.1, 116.4, 52.5, 30.2, 28.2, 14.4. **FTIR** (neat film) 3078, 2933, 1642, 1438, 1416, 1401, 1364, 1286 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>13</sub>N<sub>4</sub>S (M+H) 185.0861, found 185.0860.



**5-(Benzylthio)-2-(pent-4-enyl)-2***H***-tetrazole** (5). Diisopropyl azodicarboxylate (0.831 mL, 4.22 mmol) was added to a stirred solution of 5-benzylthio-1*H*-tetrazole (541 mg, 2.81 mmol), PPh<sub>3</sub> (1.107 g, 4.22 mmol) and pent-4-en-1-ol (315 mg, 3.66 mmol) in THF (30 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (100:0 to 90:10) gave **5** (536 mg, 73%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.67 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 7.41 (d, J = 7.4 Hz, 2H), 7.32 (t, J = 7.4 Hz, 2H), 7.30 – 7.26 (m, 1H), 5.79 (ddd, J = 16.9, 6.4, 3.8 Hz, 1H), 5.12 – 5.03 (m, 2H), 4.58 (t, J = 6.7 Hz, 2H), 4.44 (s, 2H), 2.13 – 2.07 (s, 4H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 163.4, 136.6, 136.1, 129.0, 128.5, 127.6, 116.4, 52.5, 36.5, 30.2, 28.2. **FTIR** (neat film) 3065, 2936, 1642, 1453, 1400, 1287 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>16</sub>N<sub>4</sub>NaS (M+Na) 283.0993, found 283.1003.

MeS-

N<sup>≤</sup>N<sup>−</sup> <sup>II</sup> **2-Allyl-5-(methylthio)-2***H***-tetrazole (2b)**. Following the general procedure **A** and starting from allyl alcohol (429 mg, 7.38 mmol, 1.3 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2b** (498 mg, 56%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.54 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 5.58 – 5.39 (m, 1H), 4.88 – 4.70 (m, 2H), 4.46 – 4.30 (m, 2H), 2.25 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 166.0, 130.4, 120.3, 55.3, 14.3. **FTIR** (neat film) 2989, 2933, 1647, 1416, 1398, 1353, 1277, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m*/*z*: Calcd for C<sub>5</sub>H<sub>9</sub>N<sub>4</sub>S (M+H) 157.0548, found 157.0546.

 $\mathsf{MeS} \xrightarrow[N^{\sim}N]{N^{\sim}N}$ 

**2-(But-3-enyl)-5-(methylthio)-2***H***-tetrazole (2c)**. Following the general procedure **A** and starting from but-3-en-1-ol (529 mg, 7.34 mmol, 1.3 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2c** (739 mg, 77%) as a colorless oil. **TLC**  $R_f$  0.56 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  5.42 – 5.19 (m, 1H), 4.79 – 4.69 (m, 2H), 3.91 – 3.82 (m, 2H), 2.28 (s, 3H), 2.19 – 2.12 (m, 2H). <sup>13</sup>C-NMR (151 MHz,  $C_6D_6$ )  $\delta$  165.7, 133.3, 118.3, 52.5, 33.5, 14.3. **FTIR** (neat film) 2981, 2933, 1643, 1416, 1401, 1361, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for  $C_6H_{11}N_4S$  (M+H) 171.0704, found 171.0705.

**2-(Hex-5-enyl)-5-(methylthio)-2***H***-tetrazole (2d)**. Following the general procedure **A** and starting from hex-5-en-1-ol (254 mg, 2.54 mmol, 1.3 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2d** (305 mg, 79%) as a colorless oil. **TLC**  $R_f$  0.58 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (500 MHz, CDCl<sub>3</sub>)  $\delta$  5.76 (ddt, J = 17.0, 10.2, 6.7 Hz, 1H), 5.01 (bd, J = 17.0 Hz, 1H), 4.98 (bd, J = 10.2 Hz, 1H), 4.56 (t, J = 7.1 Hz, 2H), 2.67 (s, 3H), 2.13 – 2.07 (m, 2H), 2.05 – 1.92 (m, 2H), 1.53 – 1.33 (m, 2H). <sup>13</sup>**C-NMR** (126 MHz, CDCl<sub>3</sub>)  $\delta$  164.7, 137.6, 115.3, 53.1, 32.8, 28.5, 25.5, 14.4. **FTIR** (neat film) 2932, 2861, 1641, 1437, 1400, 1362, 1055, 914 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1020.



**2-(Hept-6-enyl)-5-(methylthio)-2***H***-tetrazole (2e)**. Following the general procedure **A** and starting from hept-6-en-1-ol (703 mg, 6.16 mmol, 1.3 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2e** (771 mg, 77%) as a colorless oil. **TLC** R<sub>f</sub> 0.68 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.62 (ddt, *J* = 18.2, 9.4, 6.7 Hz, 1H), 4.98 – 4.90 (m, 2H), 3.89 – 3.81 (m, 2H), 2.29 (s, 3H), 1.78 – 1.69 (m, 2H), 1.51 – 1.37 (m, 2H), 1.09 – 0.94 (m, 2H), 0.88 – 0.76 (m, 2H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.6, 138.9, 115.2, 53.2, 33.9, 29.3, 28.6, 26.1, 14.3. **FTIR** (neat film) 2932, 2859, 1640, 1437, 1400, 1362, 1290, 1178, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 213.1174, found 213.1175.



**5-(Methylthio)-2-(oct-7-enyl)-2H-tetrazole** (**2f**). Following the general procedure **A** and starting from oct-7-en-1-ol (1.015 g, 7.92 mmol, 1.3 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2f** (1.067 g, 77%) as a colorless oil. **TLC**  $R_f$  0.69 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.70 (ddt, J = 16.9, 10.3, 6.7 Hz, 1H), 5.10 – 4.89 (m, 2H), 3.92 – 3.82 (m, 2H), 2.30 (s, 3H), 1.84 (dd, J = 14.4, 7.1 Hz, 2H), 1.49 – 1.42 (m, 2H), 1.11 – 1.04 (m, 2H), 0.97 – 0.89 (m, 2H), 0.88 – 0.80 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.7, 139.2, 115.0, 53.3, 34.2, 29.5, 29.1, 28.8, 26.5, 14.3. **FTIR** (neat film) 2931, 2858, 1640, 1438, 1400, 1361, 1284, 1054 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>19</sub>N<sub>4</sub>S (M+H) 227.1330, found 227.1324.

MeS-(N-N N=N

Me (*E*)-2-(Hex-4-enyl)-5-(methylthio)-2*H*-tetrazole (2g). Following the general procedure A and starting from (*E*)-hex-4-en-1-ol (562.8 mg, 5.62 mmol, 1.3 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave 2g (640.3 g, 75%) as a colorless oil. TLC  $R_f$  0.63 (75:25 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.21 (dqt, *J* = 12.8, 6.4, 1.2 Hz, 1H),

5.09 - 4.98 (m, 1H), 3.89 (t, J = 6.9 Hz, 2H), 2.29 (s, 3H), 1.65 - 1.59 (m, 2H), 1.58 - 1.52 (m, 2H), 1.49 (dd, J = 6.4, 1.4 Hz, 3H). <sup>13</sup>C-NMR (151 MHz,  $C_6D_6$ )  $\delta$  165.2, 129.1, 126.7, 52.2, 29.2, 28.8, 17.9, 13.9. FTIR (neat film) 2934, 1400, 1285, 1179, 1055, 968 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for  $C_8H_{15}N_4S$  (M+H) 199.1017, found 199.1013.

Me<sup>III</sup> (Z)-2-(Hex-4-enyl)-5-(methylthio)-2*H*-tetrazole (2h). Following the general procedure **A** and starting from (Z)-hex-4-en-1-ol (281 mg, 2.80 mmol, 1.3 equiv), elution with hexane/EtOAc (100:0 to 90:10) gave 2h (344 mg, 81%) as a colorless oil. TLC  $R_f$  0.65 (75:25 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.54 (dq, J = 10.8, 6.8 Hz, 1H), 5.41 – 5.29 (m, 1H), 4.55 (t, J = 6.8 Hz, 2H), 2.67 (s, 3H), 2.16 – 1.90 (m, 4H), 1.58 (d, J = 6.8 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.8, 127.8, 126.0, 52.7, 28.9, 23.5, 14.5, 12.8. FTIR (neat film) 3014, 2933, 1437, 1400, 1365, 1287 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1016.



(Z)-2-(5-Cyclopropylpent-4-enyl)-5-(methylthio)-2H-tetrazole (2i). procedure A and starting from (Z) 5 evaluation to  $1 \text{ el}^3$  (722 mg

Following the general procedure **A** and starting from (*Z*)-5-cyclopropylpent-4-en-1-ol<sup>3</sup> (732 mg, 5.80 mmol, 1.1 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2i** (849 mg, 72%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.64 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.03 (dt, *J* = 10.7, 7.4 Hz, 1H), 4.65 (ddt, *J* = 10.7, 10.0, 1.3 Hz, 1H), 4.00 – 3.88 (m, 2H), 2.28 (s, 3H), 1.86 (dd, *J* = 7.3, 7.3 Hz, 2H), 1.67 – 1.59 (m, 2H), 1.21 (dd, *J* = 6.9, 2.8 Hz, 1H), 0.54 – 0.47 (m, 2H), 0.19 – 0.13 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.5, 136.3, 125.8, 52.8, 29.5, 24.8, 14.3, 10.2, 7.5. **FTIR** (neat film) 3005, 2933, 1653, 1400, 1287, 1180, 1054 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 225.1174, found 225.1164.



**2-(4-Methylpent-4-enyl)-5-(methylthio)-2***H***-tetrazole (2j). Following the general procedure <b>A** and starting from 4-methylpent-4-en-1-ol<sup>4</sup> (478.4 mg, 4.78 mmol, 1.1 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2j** (657.3 mg, 76%) as a colorless oil. **TLC** R<sub>f</sub> 0.66 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  4.68 (d, *J* = 0.8 Hz, 1H), 4.56 (d, *J* = 0.8 Hz, 1H), 3.88 (t, *J* = 6.8 Hz, 2H), 2.29 (s, 3H), 1.67 – 1.56 (m, 4H), 1.41 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  165.3, 143.4, 111.4, 52.3, 34.1, 26.9, 22.1, 13.9. **FTIR** (neat film) 3075, 2933, 1649, 1400, 1375, 1288, 1179, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1012.

Me 2-(5-Methylhex-4-enyl)-5-(methylthio)-2*H*-tetrazole (2k). Following the general procedure A and starting from 5-methylhex-4-en-1-ol<sup>5</sup> (668.3 mg, 1.3 equiv), elution

Page S6

with hexane/EtOAc (95:5 to 85:15) gave **2k** (738.8 mg, 77%) as a colorless oil. **TLC**  $R_f$  0.76 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  4.85 (tdd, J = 7.2, 2.7, 1.4 Hz, 1H), 3.91 (t, J = 7.0 Hz, 2H), 2.29 (s, 3H), 1.71 – 1.65 (m, 1H), 1.59 (dt, J = 14.0, 7.1 Hz, 2H), 1.56 (d, J = 0.9 Hz, 3H), 1.37 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  165.6, 133.5, 123.0, 52.7, 29.5, 26.1, 25.2, 18.0, 14.3. **FTIR** (neat film) 2932, 1673, 1438, 1400, 1376, 1287, 1178, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 213.1174, found 213.1169.



**5-(Methylthio)-2-(2-vinylbenzyl)-2H-tetrazole** (21). Following the general procedure **A** and starting from (2-vinylphenyl)methanol<sup>4b, 6</sup> (592 mg, 4.41 mmol, 1.1 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2l** (602 mg, 65%, 98% estimated purity by NMR) as a colorless oil. **TLC**  $R_f 0.75$  (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  7.21 (d, J = 7.7 Hz, 1H), 6.97 – 6.90 (m, 3H), 6.90 – 6.85 (m, 1H), 5.38 (dd, J = 17.3, 1.1 Hz, 1H), 5.22 – 4.93 (m, 3H), 2.21 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  166.1, 138.1, 134.0, 131.1, 130.7, 130.6, 129.8, 127.1, 118.1, 54.4, 14.2. **FTIR** (neat film) 2932, 1697, 1491, 1415, 1399, 1355, 1054 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>11</sub>H<sub>13</sub>N<sub>4</sub>S (M+H) 233.0861, found 233.0862.



(*S*)-2-(Hex-5-en-2-yl)-5-(methylthio)-2*H*-tetrazole (2m). Following the general procedure **A** and starting from (*R*)-5-methylhex-5-en-2-ol (280 mg, 2.80 mmol, 1.3 equiv), elution with hexane/EtOAc (100: 0 to 90:10) gave 2m (355 mg, 83%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.69 (75:25 hexane/EtOAc).  $[\alpha]_D^{20}$ +60.0° (c 0.42, CHCl<sub>3</sub>). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.75 (ddt, *J* = 12.0, 10.3, 6.5 Hz, 1H), 5.04 – 4.96 (m, 2H), 4.92 (dd, *J* = 6.8, 1.5 Hz, 1H), 2.67 (s, 3H), 2.22 – 2.13 (m, 1H), 2.00 – 1.65 (m, 3H), 1.60 (d, *J* = 6.8 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.5, 136.3, 116.0, 60.3, 35.1, 29.8, 20.5, 14.5. FTIR (neat film) 3078, 2984, 2934, 1642, 1409, 1371, 1296 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1023.

**2-(5-Methylhex-5-en-2-yl)-5-(methylthio)-2H-tetrazole (2n)**. Following the general procedure **A** and starting from 5-methylhex-5-en-2-ol<sup>4b, 7</sup> (463 mg, 4.06 mmol, 1.3 equiv), elution with hexane/EtOAc (100:0 to 90:10) gave **2n** as a colorless oil (479 mg, 72%). **TLC** R<sub>f</sub> 0.71 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  4.93 (dq, J = 13.1, 6.7 Hz, 1H), 4.74 (s, 1H), 4.65 (s, 1H), 2.68 (s, 3H), 2.26 – 2.16 (m, 1H), 2.03 – 1.92 (m, 2H), 1.90 – 1.82 (m, 1H), 1.69 (s, 3H), 1.61 (d, J = 6.8 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.5, 143.6, 111.1, 60.6, 33.9, 33.7, 22.3, 20.5, 14.5. **FTIR** (neat film) 3074, 2934, 1650, 1449, 1408, 1370, 1295 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 213.1174, found 213.1173.



Me<sup>-</sup> Me<sup>-</sup> 2-(6-Methylhept-5-en-2-yl)-5-(methylthio)-2*H*-tetrazole (20). Following the general procedure **A** and starting from 6-methylhept-5-en-2-ol (359 mg, 2.80 mmol, 1.3 equiv), elution with hexane/EtOAc (100:0 to 90:10) gave **20** (428 mg, 88%) as a colorless oil. **TLC** R<sub>f</sub> 0.68 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.01 (ddd, *J* = 4.7, 4.2, 1.3 Hz, 1H), 4.95 – 4.89 (m, 1H), 2.70 (s, 3H), 2.18 – 2.04 (m, 1H), 1.98 – 1.67 (m, 3H), 1.69 (s, 3H), 1.61 (d, *J* = 6.8 Hz, 3H), 1.54 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.4, 133.3, 122.1, 60.5, 36.1, 25.7, 24.3, 20.6, 17.6, 14.5. **FTIR** (neat film) 2982, 2932, 1436, 1409, 1371, 1296 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>19</sub>N<sub>4</sub>S (M+H) 227.1330, found 227.1321.

MeS 
$$\sim N \sim N$$

<sup>||</sup> **2-(2-Methylpent-4-enyl)-5-(methylthio)-2***H***-tetrazole (2<b>p**). Following the general procedure **A** and starting from 2-methylpent-4-en-1-ol<sup>8</sup> (476.0 mg, 4.75 mmol, 1.1 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2XX** (669.4 mg, 78%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.69 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.41 (ddt, J = 17.2, 10.2, 7.2 Hz, 1H), 4.97 – 4.78 (m, 2H), 3.90 (ddd, J = 13.4, 6.2, 0.6 Hz, 1H), 3.76 (ddd, J = 13.4, 7.7, 0.7 Hz, 1H), 2.28 (s, 3H), 1.97 – 1.81 (m, 1H), 1.75 – 1.60 (m, 1H), 1.60 – 1.45 (m, 1H), 0.53 (d, J = 6.8 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 165.3, 135.2, 117.3, 57.8, 38.1, 33.4, 16.8, 13.9. **FTIR** (neat film) 3078, 2966, 2932, 1641, 1400, 1282, 1173, 918 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1010.



**2-(3-Methylpent-4-enyl)-5-(methylthio)-2H-tetrazole** (2q). Following the general procedure **A** and starting from 3-methylpent-4-en-1-ol<sup>8a, 9</sup> (478.2 g, 4.77 mmol, 1.1 equiv), elution with hexane/EtOAc (95:5 to 85:15) gave **2XX** (645.6 mg, 75%) as a colorless oil. **TLC** R<sub>f</sub> 0.69 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.26 (ddd, *J* = 17.2, 10.3, 8.0 Hz, 1H), 4.83 – 4.79 (m, 2H), 4.06 – 3.88 (m, 2H), 2.30 (s, 3H), 1.77 – 1.66 (m, 1H), 1.60 – 1.49 (m, 1H), 1.48 – 1.35 (m, 1H), 0.67 (d, *J* = 6.7 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.2, 142.2, 114.5, 51.2, 35.3, 35.3, 20.0, 14.0. **FTIR** (neat film) 3077, 2959, 1641, 1401, 1175, 1055, 917 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>4</sub>S (M+H) 199.1017, found 199.1014.



2-(2-(2-Methylenecyclopentyl)ethyl)-5-(methylthio)-2H-tetrazole (2r).

Following the general procedure **A** and starting from 2-(2-methylenecyclopentyl)ethanol<sup>10,11</sup> (158 mg, 1.25 mmol, 1.1 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2r** (197 mg, 77%) as a colorless oil. **TLC** R<sub>f</sub> 0.67 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  4.93 (d, J = 1.9 Hz, 1H), 4.82 (d, J = 1.9 Hz, 1H), 4.67 – 4.54 (m, 2H), 2.67 (s, 3H), 2.40 – 2.24 (m, 4H), 2.00 – 1.87 (m, 2H), 1.79 – 1.69 (m, 1H), 1.65 – 1.51 (m, 1H), 1.36 – 1.26 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.8, 154.7, 105.6, 52.0, 40.9, 33.6, 32.7, 32.3, 24.1, 14.5.

**FTIR** (neat film) 2953, 1652, 1400, 1363, 1285 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>10</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 225.1174, found 225.1175.



**1 2-(2-Allylcyclohexyl)-5-(methylthio)-2***H***-tetrazole (2s). Following the general procedure <b>A** and starting from *trans*-2-allylcyclohexanol<sup>4b, 12</sup> (656 mg, 4.68 mmol, 1.1 equiv), elution with hexane/EtOAc (100:0 to 90:10) gave **2s** (710 mg, 70%) as a colorless oil. **TLC**  $R_f 0.72$  (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  5.43 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H), 4.88 (d, J = 10.1 Hz, 1H), 4.79 (d, J = 17.0 Hz, 1H), 4.59 (bs, 1H), 2.29 (s, 3H), 1.87 – 1.61 (m, 6H), 1.52 – 1.35 (m, 2H), 1.29 – 1.18 (m, 1H), 1.13 – 0.95 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  164.9, 136.4, 117.1, 64.4, 40.1, 35.0, 29.2, 27.2, 23.7, 22.5, 14.4. **FTIR** (neat film) 3078, 2935, 2861, 1643, 1451, 1410, 1379, 1297 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for  $C_{11}H_{19}N_4S$  (M+H) 239.1330, found 239.1328.



(*S*)-2-((1-Allylpyrrolidin-2-yl)methyl)-5-(methylthio)-2*H*-tetrazole (2t). Following the general procedure **A** and starting from (*S*)-(1-allylpyrrolidin-2-yl)methanol<sup>4b, 13</sup> (897 mg, 7.06 mmol, 1.1 equiv), elution with hexane/EtOAc (70:30 to 60:40) gave 2t (1.092 g, 71%) as a colorless oil. **TLC**  $R_f$  0.31 (75:25 hexane/EtOAc). [ $\alpha$ ]<sup>18</sup><sub>D</sub>-26.4° (c 0.55, CHCl<sub>3</sub>). <sup>1</sup>**H**-**NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.82 – 5.67 (m, 1H), 5.09 – 5.02 (m, 1H), 4.98 – 4.88 (m, 2H), 4.14 (ddd, *J* = 13.4, 4.4, 1.5 Hz, 1H), 4.01 (ddd, *J* = 13.4, 7.8, 1.5 Hz, 1H), 3.08 – 2.97 (m, 1H), 2.80 (td, *J* = 7.2, 3.8 Hz, 1H), 2.75 – 2.64 (m, 1H), 2.29 (s, 3H), 1.92 (td, *J* = 9.3, 6.7 Hz, 1H), 1.55 – 1.49 (m, 1H), 1.45 – 1.32 (m, 2H), 1.28 – 1.20 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.5, 136.8, 117.0, 72.2, 58.1, 57.1, 54.5, 29.5, 23.4, 14.3. **FTIR** (neat film) 2980, 2804, 1644, 1400, 1376, 1264, 1097 cm<sup>-1</sup>. **HRMS** (ESI) *m*/*z*: Calcd for C<sub>10</sub>H<sub>18</sub>N<sub>5</sub>S (M+H) 240.1283, found 240.1285.



 $^{N}$  (*R*)-(1-Allylpiperidin-2-yl)methanol. LiAlH<sub>4</sub> (517 mg, 13.6 mmol) was added to a 0 °C cooled solution of (*R*)-methyl 1-allylpiperidine-2-carboxylate<sup>14,15</sup> (1.915 g, 10.5 mmol) in THF (100 mL). The suspension was allowed to warm to r.t. and stirred for 1 h. Then, H<sub>2</sub>O (0.5 mL) was added dropwise, followed by 15% aq. NaOH (0.5 mL), and H<sub>2</sub>O (1.5 mL). The resulting mixture was stirred for 15 min. The resulting suspension was filtered through a pad of Celite, and the pad was washed with methanol. The combined organic fractions were concentrated under reduced pressure to give the entitled compound (1.513 g, 93%) as a yellowish oil. **TLC** R<sub>f</sub> 0.16 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). [α]<sup>18</sup><sub>D</sub>+21.2° (c 0.54, CHCl<sub>3</sub>). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.86 (dddd, *J* = 17.6, 10.2, 7.6, 5.5 Hz, 1H), 5.19 – 5.11 (m, 2H), 3.77 (dd, *J* = 10.8, 4.2 Hz, 1H), 3.49 – 3.37 (m, 2H), 2.99 (dd, *J* = 14.1, 7.6 Hz, 1H), 2.96 – 2.90 (m, 1H), 2.61 (bs, 1H), 2.39 – 2.32 (m, 1H), 2.27 – 2.18 (m, 1H), 1.75 – 1.66 (m, 1H), 1.66 – 1.51 (m, 3H), 1.46 – 1.36 (m, 1H), 1.35 – 1.25 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 135.2, 117.4, 62.3, 60.2, 56.4, 51.2, 27.6, 24.5, 23.5. **FTIR** (neat film) 3374, 2934, 1643, 1444, 1062 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>9</sub>H<sub>18</sub>NO (M+H) 156.1388, found 156.1381.



(*R*)-1-Allyl-2-((5-(methylthio)-2*H*-tetrazol-2-yl)methyl)piperidine (2u). Following the general procedure **A** and starting from (*R*)-(1-allylpiperidin-2-yl)methanol (942 mg, 6.07 mmol, 1.1 equiv), elution with hexane/EtOAc (70:30 to 60:40) gave **3u** (542 mg, 39%, 96% estimated purity by NMR)<sup>16</sup> as a colorless oil. **TLC** R<sub>*f*</sub> 0.41 (75:25 hexane/EtOAc). [ $\alpha$ ]<sup>18</sup><sub>D</sub>+29.9° (c 0.59, CHCl<sub>3</sub>). <sup>1</sup>**H**-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.62 (ddd, *J* = 12.6, 10.4, 6.3 Hz, 1H), 4.99 – 4.88 (m, 2H), 4.69 – 4.57 (m, 1H), 2.93 – 2.73 (m, 4H), 2.38 (dd, *J* = 12.3, 6.7 Hz, 1H), 2.31 (s, 3H), 2.30 – 2.26 (m, 1H), 2.10 – 1.97 (m, 1H), 1.88 – 1.79 (m, 1H), 1.57 – 1.47 (m, 1H), 1.45 – 1.35 (m, 1H), 1.35 – 1.24 (m, 2H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.1, 136.5, 117.5, 65.2, 62.1, 58.4, 56.0, 33.9, 29.5, 22.9, 14.4. **FTIR** (neat film) 2932, 2805, 1643, 1403, 1345, 1290, 1094, 1054 cm<sup>-1</sup>. **HRMS** (ESI) *m*/*z*: Calcd for C<sub>11</sub>H<sub>20</sub>N<sub>5</sub>S (M+H) 254.1439, found 254.1438.



(*S*)-(1-(2-Methylallyl)indolin-2-yl)methanol. 3-Bromo-2-methylprop-1-ene (1.075 g, 7.97 mmol) was added to a solution of (*S*)-indolin-2-ylmethanol<sup>4b,17</sup> (792.3 mg, 5.31 mmol) and Et<sub>3</sub>N (1.48 mL, 10.62 mmol) in THF (20 mL) at r.t. The reaction mixture was heated to 40 °C and stirred for 6 h. Then, solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography and elution with hexane/EtOAc (80:20 to 70:30) gave the entitled compound (780.5 mg, 72%) as a yellowish oil. **TLC** R<sub>*f*</sub> 0.36 (75:25 hexane/EtOAc).  $[\alpha]_{1D}^{18}$ -38.3° (c 0.12, CHCl<sub>3</sub>). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.12 – 6.98 (m, 2H), 6.69 (td, *J* = 7.4, 0.9 Hz, 1H), 6.49 (d, *J* = 7.8 Hz, 1H), 5.10 – 4.95 (m, 1H), 4.95 – 4.85 (m, 1H), 3.83 (dt, *J* = 11.6, 3.5 Hz, 1H), 3.75 (tt, *J* = 9.5, 3.5 Hz, 1H), 3.69 – 3.60 (m, 3H), 3.14 (dd, *J* = 15.9, 9.5 Hz, 1H), 3.04 (dd, *J* = 15.9, 9.5 Hz, 1H), 1.94 – 1.84 (m, 1H), 1.78 (d, *J* = 0.5 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  153.1, 143.1, 128.5, 127.4, 124.2, 118.2, 111.1, 107.7, 67.0, 63.0, 55.5, 31.3, 20.5. **FTIR** (neat film) 3387, 3050, 2914, 1654, 1606, 1487, 1266, 1024 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>18</sub>NO (M+H) 204.1388, found 204.1379.



Me (*S*)-1-(2-Methylallyl)-2-((5-(methylthio)-2*H*-tetrazol-2-yl)methyl)indoline (2v). Following the general procedure **A** and starting from (*S*)-(1-(2methylallyl)indolin-2-yl)methanol (602 mg, 2.96 mmol, 1.1 equiv), elution with hexane/EtOAc (85:15 to 75:25) gave 2v (614 mg, 76%, 95% estimated purity by NMR)<sup>16</sup> as a pinkish oil. **TLC**  $R_f 0.61 (75:25 hexane/EtOAc). [α]_D^{19}-23.4^\circ$  (c 0.66, CHCl<sub>3</sub>). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 7.01 (dd, *J* = 7.7, 7.5 Hz, 1H), 6.85 (dd, *J* = 7.3, 0.7 Hz, 1H), 6.68 (dd, *J* = 7.5, 7.3 Hz, 1H), 6.33 (d, *J* = 7.7 Hz, 1H), 4.82 (bs, 1H), 4.74 (bs, 1H), 4.23 – 4.12 (m, 1H), 3.97 (ddd, *J* = 13.5, 8.0, 2.8 Hz, 1H), 3.75 - 3.65 (m, 1H), 3.23 - 3.19 (m, 2H), 2.68 (dd, J = 16.1, 9.3 Hz, 1H), 2.62 (dd, J = 16.1, 7.2 Hz, 1H), 2.27 (s, 3H), 1.46 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  165.9, 152.3, 142.5, 128.7, 127.6, 125.0, 119.0, 112.5, 108.1, 63.9, 56.0, 55.0, 34.0, 20.6, 14.3. **FTIR** (neat film) 3074, 3051, 2932, 1656, 1607, 1486, 1399, 1054, 747 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for  $C_{15}H_{20}N_5S$  (M+H) 302.1439, found 302.1440.



 $\checkmark$  2-(2-(Allyloxy)ethyl)-5-(methylthio)-2*H*-tetrazole (2w). Following the general procedure **A** and starting from 2-(allyloxy)ethanol (800 mg, 7.83 mmol, 1.3 equiv), elution with hexane/EtOAc (80:20 to 70:30) gave 2w as a colorless oil (979 mg, 81%). TLC R<sub>f</sub> 0.42 (75:25 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 5.55 (ddt, *J* = 21.8, 10.6, 5.4 Hz, 1H), 5.05 − 4.84 (m, 2H), 4.02 (dd, *J* = 7.4, 3.7 Hz, 2H), 3.54 − 3.44 (m, 2H), 3.33 (dd, *J* = 7.4, 3.3 Hz, 2H), 2.24 (s, 3H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 165.8, 134.8, 117.2, 72.1, 67.3, 53.1, 14.3. FTIR (neat film) 2933, 2870, 1721, 1402, 1348, 1284, 1109 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>13</sub>N<sub>4</sub>OS (M+H) 201.0810, found 201.0814.



**5-(Methylthio)-2-(2-(vinyloxy)ethyl)-2H-tetrazole** (**2x**). Following the general procedure **A** and starting from 2-(vinyloxy)ethanol (513 mg, 5.82 mmol, 1.3 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2x** (648 mg, 78%) as a colorless oil. **TLC**  $R_f$  0.40 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  6.06 (dd, J = 14.4, 6.8 Hz, 1H), 3.98 – 3.92 (m, 2H), 3.92 – 3.87 (m, 1H), 3.80 (dd, J = 6.8, 2.3 Hz, 1H), 3.52 – 3.37 (m, 2H), 2.22 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  166.0, 151.3, 87.7, 64.8, 52.2, 14.3. **FTIR** (neat film) 2934, 2884, 1622, 1402, 1322, 1200, 961 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for  $C_6H_{11}N_4OS$  (M+H) 187.0654, found 187.0645.

(Z)-2-(5-Methoxy-4-methylpent-4-enyl)-5-(methylthio)-2*H*-tetrazole (2y) and (*E*)-2-(5-Methoxy-4-methylpent-4-enyl)-5-(methylthio)-2*H*-tetrazole (2z). Following the general procedure **A** and starting from (*Z*/*E*)-5-methoxy-4-methylpent-4-en-1-ol<sup>4b. 18</sup> (305 mg, 2.33 mmol, 37:63 *Z*/*E*-mixture, 1.3 equiv), elution with hexane/EtOAc (90:10 to 60:40) gave 2y (132 mg, 86%) and 2z (219 mg, 85%) as colorless oils.

MeO **2y**: **TLC** R<sub>f</sub> 0.53 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>) δ 5.80 (bs, 1H), 4.51 (t, J = 7.4 Hz, 2H), 3.50 (s, 3H), 2.66 (s, 3H), 2.20 – 2.02 (m, 4H), 1.53 (d, J = 1.3 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>) δ 164.6, 142.9, 111.3, 59.2, 53.0, 26.8, 25.6, 17.0, 14.5. **FTIR** (neat film) 2932, 1684, 1400, 1220, 1139 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>16</sub>N<sub>4</sub>NaOS (M+Na<sup>+</sup>) 251.0943, found 251.0933.

OMe 2z: TLC  $R_f$  0.47 (75:25 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.78 (d, J = 1.2 Hz, 1H), 4.52 (t, J = 7.0 Hz, 2H), 3.55 (s, 3H), 2.67 (s, 3H), 2.06 (p, J = 7.2 Hz, 2H), 1.91 (t, J = 7.2 Hz, 2H), 1.58 (d, J = 1.2 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.8, 143.2, 110.9, 59.3, 52.5, 30.4, 27.1, 14.4, 12.4. FTIR (neat film) 2933, 1685, 1400, 1204, 1125 cm<sup>-1</sup>. HRMS (ESI) m/z: Calcd for C<sub>9</sub>H<sub>16</sub>N<sub>4</sub>NaOS (M+Na<sup>+</sup>) 251.0943, found 251.0945.



**2aa: TLC**  $R_f$  0.65 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.92 (dd, J = 3.5, 1.7 Hz, 1H), 4.64 – 4.46 (m, 2H), 3.51 (s, 3H), 2.80 – 2.70 (m, 1H), 2.66 (s, 3H), 2.32 – 2.22 (m, 1H), 2.21 – 2.11 (m, 2H), 2.03 – 1.92 (m, 1H), 1.88 (dt, J = 13.4, 7.4 Hz, 1H), 1.76 – 1.60 (m, 1H), 1.56 – 1.45 (m, 1H), 1.42 – 1.31 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.5, 140.1, 122.1, 59.3, 52.5, 36.8, 33.9, 32.6, 28.8, 25.0, 14.5. **FTIR** (neat film) 2934, 1723, 1400, 1362, 1284 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>18</sub>N<sub>4</sub>ONaS (M+Na) 277.1099, found 277.1093.



**2bb**: **TLC**  $R_f$  0.53 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.88 (dd, J = 4.2, 2.2 Hz, 1H), 4.70 – 4.50 (m, 2H), 3.57 (s, 3H), 2.67 (s, 3H), 2.41 – 2.29 (m, 2H), 2.29 – 2.19 (m, 1H), 2.18 – 2.04 (m, 1H), 1.98 – 1.81 (m, 2H), 1.80 – 1.68 (m, 1H), 1.67 – 1.51 (m, 1H), 1.39 – 1.24 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  164.8, 140.2, 122.5, 59.6, 51.9, 38.2, 34.1, 32.8, 26.6, 24.0, 14.4. **FTIR** (neat film) 2935, 1723, 1401, 1362, 1119 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>11</sub>H<sub>18</sub>N<sub>4</sub>ONaS (M+Na) 277.1099, found 277.1101.



**5-(Methylthio)-2-(pent-4-ynyl)-2H-tetrazole** (**2cc**). Following the general procedure **A** and starting from pent-4-yn-1-ol (235 mg, 2.80 mmol, 1.3 equiv), elution with hexane/EtOAc (90:10 to 80:20) gave **2cc** (331 mg, 84%) as a colorless oil. **TLC**  $R_f$  0.54 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (500 MHz, CDCl<sub>3</sub>)  $\delta$  4.69 (t, J = 6.7 Hz, 2H), 2.66 (s, 3H), 2.33 – 2.26 (m, 2H), 2.21 (p, J = 6.7 Hz, 2H), 2.02 (t, J = 2.5 Hz, 1H). <sup>13</sup>**C-NMR** (126 MHz, CDCl<sub>3</sub>)  $\delta$  165.0, 81.7, 70.0, 51.9, 27.8, 15.7, 14.4. **FTIR** (neat film) 3291, 2934, 2119, 1435, 1401, 1287, 1056 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>7</sub>H<sub>11</sub>N<sub>4</sub>S (M+H) 183.0704, found 183.0709.

OMe 2-(4,4-Dimethoxybutyl)-5-(methylthio)-2*H*-tetrazole. Following the general procedure **A** and starting from 4,4-dimethoxybutan-1-ol<sup>21</sup> (644.5 mg, 4.80 mmol, 1.1 equiv), elution with hexane/EtOAc (35:65 to 45:55) gave 2-(4,4-dimethoxybutyl)-5-(methylthio)-2*H*-tetrazole (828.8 mg, 82%) as a colorless oil. TLC R<sub>f</sub> 0.60 (50:50 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  4.00 (t, J = 5.5 Hz, 1H), 3.92 (t, J = 7.2 Hz, 2H), 2.99 (s, 6H), 2.27 (s, 3H), 1.70 – 1.64 (m, 2H), 1.31 (ddd, J = 9.7, 7.7, 5.6 Hz, 2H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  165.3, 103.7, 52.7, 52.5, 29.3, 24.5, 21.6, 13.9. FTIR (neat film) 2936, 2832, 1801, 1739, 1400, 1265, 1127, 1095 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>16</sub>N<sub>4</sub>O<sub>2</sub>SNa (M+Na) 255.0892, found 255.0886.



<sup>0</sup> **4-(5-(Methylthio)-2***H***-tetrazol-2-yl)butanal (2dd)**. LiBF<sub>4</sub> (308.5 mg, 3.29 mmol) was added to a solution of 2-(4,4-dimethoxybutyl)-5-(methylthio)-2*H*-tetrazole (254.8 mg, 1.10 mmol) in MeCN - H<sub>2</sub>O (10 mL, 98:2%), and the mixture was stirred for 21 h at r.t. Solvents were removed under reduced pressure, the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with H<sub>2</sub>O and brine. The organic phase was dried over MgSO<sub>4</sub> and concentrated under reduced pressure. The residue was purified by silica gel chromatography, and elution with hexane/EtOAc (50:50 to 40:60) gave **2dd** (175.1 mg, 86%, 98% estimated purity by NMR) as a colorless oil. **TLC** R<sub>f</sub> 0.50 (50:50 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.95 (d, *J* = 7.6 Hz, 1H), 3.82 – 3.76 (m, 2H), 2.28 (s, 3H), 1.61 – 1.54 (m, 2H), 1.49 – 1.41 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  199.0, 165.8, 52.1, 40.1, 21.8, 14.3. **FTIR** (neat film) 2935, 1722, 1401, 1320, 1056 cm<sup>-1</sup>. **HRMS** (API) *m*/*z*: Calcd for C<sub>6</sub>H<sub>11</sub>N<sub>4</sub>OS (M+H) 187.0654, found 187.0647.

N<sup>-1</sup> C N 4-(5-(Methylthio)-2*H*-tetrazol-2-yl)butanenitrile (2ee). Following the general procedure **A** and starting from 4-hydroxybutanenitrile<sup>8a, 22</sup> (488.2 mg, 5.74 mmol, 1.3 equiv), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeCN (95:5 to 90:10) gave **2XX** (582.1 mg, 72%) as a colorless oil. **TLC** R<sub>f</sub> 0.54 (50:50 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  3.67 – 3.59 (m, 2H), 2.26 (s, 3H), 1.24 – 1.12 (m, 4H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  166.1, 118.2, 51.1, 25.1, 14.3, 14.2. **FTIR** (neat film) 2934, 2249, 1770, 1401, 1286, 1180, 1155, 1016 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>6</sub>H<sub>10</sub>N<sub>5</sub>S (M+H) 184.0657, found 184.0651.

 $Me \xrightarrow{N \\ N}^{N \\ N}$ 

MeS-<

**5-Methyl-2-(pent-4-enyl)-2H-tetrazole** (11). Diisopropyl azodicarboxylate (1.77 mL, 9.01 mmol) was added to a stirred solution of 5-methyl-1*H*-tetrazole (504.9 mg, 6.01 mmol), PPh<sub>3</sub> (2.36 g, 9.01 mmol) and pent-4-en-1-ol (0.795 mL, 7.81 mmol) in THF (50 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (80:20 to 70:30) gave **11** (601.2 mg, 66%) as a colorless oil. **TLC** R<sub>f</sub>

0.40 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  5.44 (ddt, J = 16.9, 10.4, 6.5 Hz, 1H), 4.93 – 4.79 (m, 2H), 3.94 (t, J = 6.8 Hz, 2H), 2.26 (s, 3H), 1.68 – 1.57 (m, 4H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  163.4, 137.0, 116.4, 52.0, 30.7, 28.7, 11.1. **FTIR** (neat film) 3080, 2978, 2942, 1642, 1504, 1446, 1360, 1192, 1033, 918 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>13</sub>N<sub>4</sub> (M+H) 153.1140, found 153.1141.

**Ethyl 2-(pent-4-enyl)-2H-tetrazole-5-carboxylate** (13). Diisopropyl azodicarboxylate (0.470 mL, 2.39 mmol) was added to a stirred suspension of ethyl 1*H*-tetrazole-5-carboxylate (226.3 mg, 1.59 mmol), PPh<sub>3</sub> (626.5 mg, 2.39 mmol) and pent-4-en-1-ol (0.211 mL, 2.07 mmol) in THF (20 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (95:5 to 70:30) gave **13** (152.1 mg, 45%) as a colorless oil. **TLC**  $R_f$  0.44 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.36 (ddt, J = 16.9, 10.2, 6.6 Hz, 1H), 4.92 – 4.74 (m, 2H), 4.11 (q, J = 7.1 Hz, 2H), 3.84 (t, J = 7.0 Hz, 2H), 1.54 (td, J = 7.5, 1.1 Hz, 2H), 1.48 (qd, J = 7.5, 1.1 Hz, 2H), 0.98 (t, J = 7.1 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  158.6, 158.2, 136.2, 116.2, 62.0, 52.5, 30.2, 28.0, 14.0. **FTIR** (neat film) 3079, 2982, 2939, 1736, 1641, 1507, 1448, 1277, 1182, 1156 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>15</sub>N<sub>4</sub>O<sub>2</sub> (M+H) 211.1195, found 211.1194.



**2-(Pent-4-enyl)-5-phenyl-2H-tetrazole** (15).<sup>23</sup> Diisopropyl azodicarboxylate (0.624 mL, 3.17 mmol) was added to a stirred solution of 5-phenyl-1*H*-tetrazole (308.9 mg, 2.11 mmol), PPh<sub>3</sub> (831.5 mg, 3.17 mmol) and pent-4-en-1-ol (236.7 mg, 2.75 mmol) in THF (40 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (95:5 to 80:20) gave **15** (412.0 mg, 91%) as a colorless oil. **TLC** R<sub>f</sub> 0.76 (75:25 hexane/EtOAc). **<sup>1</sup>H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  8.42 (d, *J* = 7.8 Hz, 2H), 7.18 (dd, *J* = 7.8, 7.4 Hz, 2H), 7.11 (t, *J* = 7.4 Hz, 1H), 5.43 (ddt, *J* = 16.9, 10.3, 6.5 Hz, 1H), 4.89 – 4.83 (m, 2H), 3.95 (t, *J* = 6.7 Hz, 2H), 1.68 – 1.56 (m, 4H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.6, 136.6, 130.3, 129.2, 128.6, 127.2, 116.1, 52.0, 30.4, 28.3. **FTIR** (neat film) 3076, 2979, 2950, 1642, 1530, 1466, 1450, 1358, 1045, 918 cm<sup>-1</sup>. **MS** (ESI) *m/z*: 215 (M+H, 14), 237 (M+Na, 100). The spectroscopic data matches the product reported in literature.<sup>23</sup>

#### C. Synthesis of Fused Pyrazoline, and Pyrazole Derivatives 3, 4, 6 – 8, 14 and 16.

MeS 2-(Methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole (3a). Following the general procedure **B** and starting from 2a (604.6 mg, 3.28 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 65:35) gave 3a as a yellowish oil (328 mg, 64%). TLC R<sub>f</sub> 0.28 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 3.71 – 3.61 (m, 1H), 3.44 – 3.47 (m, 1H), 2.94 (ddd, J = 12.1, 9.0, 7.2 Hz, 1H), 2.63 (dd, J = 16.2, 9.2 Hz, 1H), 2.25 (s, 3H), 2.22 (d, J = 16.2 Hz, 1H), 1.49 – 1.36 (m, 1H), 1.31 (dd, J = 12.4, 7.6 Hz, 1H), 1.26 – 1.16 (m, 1H), 1.08 – 0.96 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 150.9, 65.2, 55.6, 44.3, 31.8, 24.8, 14.1. FTIR (neat film) 2959, 2872, 1609, 1449, 1128, 1058 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>13</sub>N<sub>2</sub>S (M+H) 157.0799, found 157.0796.

S =  $(1 \text{ N})^{-1}$  Tetrahydro-1*H*-pyrrolo[1,2-*b*]pyrazole-2(3*H*)-thione (4a). Following the general procedure **B**, starting from 2a (53.7 mg, 0.29 mmol), irradiation at r.t. for 16 h, and elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave 4a as a yellowish oil (12.8 mg, 31%, 83% estimated purity by NMR). TLC R<sub>f</sub> 0.50 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>) δ 4.20 – 4.11 (m, 1H), 3.28 (dd, *J* = 18.1, 9.8 Hz, 1H), 3.21 – 3.07 (m, 2H), 2.95 (dd, *J* = 18.1, 5.4 Hz, 1H), 2.08 (ddd, *J* = 15.9, 12.9, 8.0 Hz, 1H), 1.99 – 1.90 (m, 1H), 1.89 – 1.78 (m, 1H), 1.79 – 1.69 (m, 1H), 1.70 – 1.60 (m, 1H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>) δ 190.5, 63.6, 57.0, 50.1, 32.0, 23.7. FTIR (neat film) 3417, 2957, 1512, 1447, 1268, 1121 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>6</sub>H<sub>11</sub>N<sub>2</sub>S (M+H) 143.0643, found 143.0645.

BnS 2-(Benzylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole (6). Following the general procedure **B** and starting from **5** (54.9 mg, 0.21 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (85:15 to 75:25) gave **6** as a yellowish oil (31.9 mg, 65%, 98% estimated purity by NMR). **TLC**  $R_f$  0.54 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H**-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.29 (d, *J* = 7.4 Hz, 2H), 7.06 (t, *J* = 7.4 Hz, 2H), 6.99 (t, *J* = 7.4 Hz, 1H), 4.25 (d, *J* = 13.3 Hz, 1H), 4.19 (d, *J* = 13.3 Hz, 1H), 3.71 – 3.65 (m, 1H), 3.42 (m, 1H), 2.94 (ddd, *J* = 12.1, 9.2, 6.8 Hz, 1H), 2.58 (dd, *J* = 16.1, 9.3 Hz, 1H), 2.15 (dd, *J* = 16.1, 1.7 Hz, 1H), 1.43 – 1.33 (m, 1H), 1.31 – 1.16 (m, 2H), 0.99 – 0.91 (m, 1H). <sup>13</sup>**C**-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  149.9, 138.7, 129.8, 129.0, 127.7, 65.1, 55.6, 44.4, 36.0, 31.8, 24.7. **FTIR** (neat film) 2957, 2868, 1683, 1602, 1561, 1495, 1453, 1267, 1070 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 233.1112, found 233.1107.

MeS  $\longrightarrow$  3-(Methylthio)-1,2-diazabicyclo[3.1.0]hex-2-ene (3b). Following the general procedure **B** and starting from 2b (46.6 mg, 0.30 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/TBME (30:70 to 20:80) gave 3b as a yellowish oil (26.0 mg, 68%). TLC R<sub>f</sub> 0.20 (50:50 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  2.42 (dd, J = 17.3, 7.6 Hz, 1H), 2.36 (dd, J = 17.3, 2.2 Hz, 1H), 2.16 (s, 3H), 2.13 – 2.08 (m, 1H), 1.78 (dd, J = 6.0, 1.8 Hz, 1H), 0.80 – 0.76 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  166.9, 41.4, 40.9, 39.3, 14.2. FTIR (neat film) 2918, 2849, 1549, 1428, 1290, 1134, 1103 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>5</sub>H<sub>9</sub>N<sub>2</sub>S (M+H) 129.0486, found 129.0487.

# MeS-

**2-(Methylthio)-3,3a,4,5,6,7-hexahydropyrazolo**[1,5-*a*]**pyridine** (**3d**). Following the general procedure **B** and starting from **2d** (56.6 mg, 0.29 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (90:10 to 80:20) gave **3d** as a yellowish oil (27.1 mg, 56%). **TLC** R<sub>*f*</sub> 0.69 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.94 – 3.85 (m, 1H), 2.65 – 2.52 (m, 2H), 2.30 (dd, J = 14.6, 7.5 Hz, 1H), 2.27 (s, 3H), 2.11 (dd, J = 14.6, 11.3 Hz, 1H), 1.60 – 1.51 (m, 1H), 1.49 – 1.40 (m, 1H), 1.31 (tdd, J = 11.3, 9.4, 3.8 Hz, 2H), 1.27 – 1.18 (m, 1H), 1.03 – 0.88 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  150.0, 67.1, 53.3, 43.2, 28.6, 25.6, 24.7, 13.9. **FTIR** (neat film) 2933, 2852, 2793, 1539, 1440, 1277, 1259, 1026 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0953.

MeS 2-(Methylthio)-3a,4,5,6,7,8-hexahydro-3*H*-pyrazolo[1,5-*a*]azepine (3e). Following the general procedure **B** and starting from 3e (105.4 mg, 0.50 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/TBME (90:10 to 60:40) gave the monomer 3e (23.7 mg, 26%, 99% estimated purity by NMR), and its quasidimer (21.6 mg, 22%, characterized below) as yellowish oils. When this reaction was conducted three times more diluted (0.10 M), 3e was obtained in 35% and its quasidimer only in a 4% yield. 3e: TLC R<sub>f</sub> 0.62 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.00 (dt, *J* = 12.1, 5.8 Hz, 1H), 2.86 (dtd, *J* = 13.4, 9.6, 3.8 Hz, 1H), 2.63 (ddd, *J* = 12.1, 8.9, 4.8 Hz, 1H), 2.51 (dd, *J* = 15.7, 9.6 Hz, 1H), 2.26 (s, 3H), 2.24 – 2.14 (m, 1H), 1.75 – 1.67 (m, 1H), 1.59 – 1.49 (m, 2H), 1.48 – 1.16 (m, 5H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  148.7, 69.1, 57.3, 45.9, 33.9, 28.5, 27.5, 26.3, 13.9. FTIR (neat film) 2924, 1660, 1502, 1463, 1442, 1136 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 185.1112, found 185.1106.



(3*R*\*,3a*R*\*)-3-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-pyrrolo-[1,2-*b*]pyrazole (3g). Following the general procedure **B** and starting from 2g (63.1 mg, 0.32 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave 3g as a yellowish oil (34.9 mg, 64%), d.r. (19:1 dr). Major diastereomer: **TLC** R<sub>*f*</sub> 0.28 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 3.72 – 3.63 (m, 1H), 3.15 (ddd, J = 8.3, 6.8, 1.4 Hz, 1H), 2.94 (ddd, J = 12.2, 9.1, 7.1 Hz, 1H), 2.54 (qd, J = 7.2, 1.4 Hz, 1H), 2.25 (s, 3H), 1.54 – 1.42 (m, 1H), 1.42 – 1.31 (m, 1H), 1.29 – 1.19 (m, 1H), 1.13 – 1.07 (m, 4H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 155.5, 73.2, 54.8, 51.6, 30.7, 24.3, 18.1, 13.5. **FTIR** (neat film) 2966, 2928, 2870, 1558, 1452, 1119, 1021 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0948.



Mè  $\sqcap$  (3*S*\*,3a*R*\*)-3-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo-[1,2-*b*]pyrazole (3h). Following the general procedure **B** and starting from *Z*-2h (103.7 mg, 0.52 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3h as a yellowish oil (55.3 mg, 62%), d.r. (18:2). Major diastereomer: **TLC** R<sub>f</sub> 0.34 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.66 (m, 1H), 3.46 (dd, *J* = 14.7, 8.2 Hz, 1H), 3.12 (dt, *J* = 12.1, 7.5 Hz, 1H), 3.04 (dq, *J*  = 14.7, 7.3 Hz, 1H), 2.25 (s, 3H), 1.54 – 1.40 (m, 1H), 1.39 – 1.31 (m, 1H), 1.31 – 1.21 (m, 1H), 1.07 – 0.96 (m, 1H), 0.94 (d, J = 7.3 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  154.8, 70.4, 55.8, 46.8, 25.1, 24.2, 13.8, 12.0. FTIR (neat film) 2927, 1670, 1561, 1451, 1378, 1184 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0958.



#### (3S\*,3aR\*)-3-Cyclopropyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-

**pyrrolo**[1,2-*b*]**pyrazole** (**3i**). Following the general procedure **B** and starting from **2i** (38.1 mg, 0.17 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/TBME (30:70 to 20:80) gave **3i** as a yellowish oil (20.3 mg, 61%), d.r. (17:3). Major diastereomer: **TLC** R<sub>f</sub> 0.18 (75:25 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.71 (ddd, J = 12.2, 7.6, 4.9 Hz, 1H), 3.56 (dd, J = 16.5, 8.0 Hz, 1H), 3.12 (dt, J = 12.2, 7.6 Hz, 1H), 2.31 (s, 3H), 2.11 (dd, J = 10.4, 8.9 Hz, 1H), 1.66 – 1.50 (m, 2H), 1.39 – 1.22 (m, 2H), 0.65 – 0.48 (m, 2H), 0.32 – 0.13 (m, 2H), -0.13 – -0.24 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  154.8, 69.7, 58.9, 55.9, 25.4, 25.2, 13.8, 8.8, 6.1, 3.8. **FTIR** (neat film) 3095, 2961, 2870, 1553, 1430, 1250, 1154, 1021 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 197.1112, found 197.1115.



Me **3a-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazole** (**3j**). Following the general procedure **B** and starting from **2j** (62.8 mg, 0.32 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave **3j** as a yellowish oil (37.9 mg, 70%, 99% estimated purity by NMR). **TLC** R<sub>*f*</sub> 0.30 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.66 – 3.60 (m, 1H), 3.04 – 2.98 (m, 1H), 2.46 (d, *J* = 16.0 Hz, 1H), 2.42 (d, *J* = 16.0 Hz, 1H), 2.25 (s, 3H), 1.59 – 1.51 (m, 1H), 1.42 – 1.32 (m, 2H), 1.21 – 1.14 (m, 1H), 1.06 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  150.0, 73.1, 53.9, 50.8, 37.4, 26.2, 24.9, 13.5. **FTIR** (neat film) 2961, 2927, 2869, 1562, 1449, 1313, 1149, 1062 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0953.



Me Me **3,3-Dimethyl-2-(methylthio)-3a,4,5,6-tetrahydro-3***H***-pyrrolo**[**1,2-***b*]**pyrazole** (**3k**). Following the general procedure **B** and starting from **2k** (65.6 mg, 0.31 mmol), elution with hexane/EtOAc (60:40 to 40:60) gave **3k** as a yellowish oil (38.2 mg, 67%, 96% estimated purity by NMR). **TLC** R<sub>*f*</sub> 0.21 (50:50 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 3.64 (ddd, J = 7.8, 6.8, 4.2 Hz, 1H), 3.21 – 3.11 (m, 1H), 3.11 – 3.03 (m, 1H), 2.25 (s, 3H), 1.61 – 1.48 (m, 1H), 1.42 – 1.28 (m, 2H), 1.26 (s, J = 4.4 Hz, 3H), 1.12 – 1.03 (m, 1H), 1.01 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 157.9, 77.4, 54.9, 51.5, 26.5, 25.2, 25.1, 20.2, 13.3. **FTIR** (neat film) 2964, 2927, 1553, 1443, 1286, 1109 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 185.1112, found 185.1108.



**2-(Methylthio)-3a,8-dihydro-3***H***-pyrazolo[5,1-***a***]isoindole (3I). Following the general procedure <b>B** and starting from **2l** (59.3 mg, 0.26 mmol), elution with hexane/EtOAc (60:40 to 50:50) gave **3l** as a yellowish oil (36.5 mg, 70%). **TLC**  $R_f$  0.31 (50:50) hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  7.04 – 6.97 (m, 2H), 6.88 (d, *J* = 5.8 Hz, 1H), 6.75 (d, *J* = 5.8 Hz, 1H), 4.83 (d, *J* = 15.7 Hz, 1H), 4.59 (d, *J* = 9.5 Hz, 1H), 4.36 (d, *J* = 15.7 Hz, 1H), 2.78 (dd, *J* = 15.9, 9.5 Hz, 1H), 2.67 (dd, *J* = 15.9, 1.4 Hz, 1H), 2.09 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  151.3, 143.6, 140.2, 128.7, 127.6, 123.6, 123.2, 70.6, 61.0, 43.2, 14.0. **FTIR** (neat film) 2923, 2848, 1562, 1431, 1287, 1156, 1117 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for  $C_{11}H_{13}N_2S$  (M+H) 205.0799, found 205.0791.



<sup>H</sup> (3a*R*\*,6*S*)-6-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole (3m). Following the general procedure **B** and starting from 2m (57.7 mg, 0.29 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3m as a yellowish oil (37.8 mg, 76%), d.r. (17:3).



**NOESY** H Major diastereomer: (3a*R*,6*S*)-6-Methyl-2-(methylthio)-3a,4,5,6tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole. TLC  $R_f$  0.47 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). [ $\alpha$ ]<sup>19</sup><sub>D</sub>+36.5° (c 0.39, CHCl<sub>3</sub>). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.74 (dq, *J* = 13.0, 6.7 Hz, 1H), 3.60 – 3.52 (m, 1H), 2.57 (dd, *J* = 16.1, 9.6 Hz, 1H), 2.26 (s, 3H), 2.23 (dd, *J* = 16.1, 2.3 Hz, 1H), 1.71 – 1.61 (m, 1H), 1.48 – 1.38 (m, 1H), 1.18 (d, *J* = 6.7 Hz, 3H), 1.12 – 1.00 (m, 2H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  150.0, 64.2, 62.5, 43.3, 32.5, 31.5, 21.7, 14.2. FTIR (neat film) 2958, 2924, 2853, 1660, 1632, 1601, 1456, 1377 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0958.



(3aR\*,6S\*)-3a,6-Dimethyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-

**pyrrolo**[1,2-*b*]**pyrazole** (**3n**). Following the general procedure **B** and starting from **2n** (33.9 mg, 0.16 mmol), elution with hexane/EtOAc (80:20 to 70:30) gave **3n** as a yellowish oil (21.2 mg, 72%), d.r. (17:3). Major diastereomer: **TLC**  $R_f$  0.50 (50:50 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  3.40 (dq, J = 15.1, 6.7 Hz, 1H), 2.78 (d, J = 16.5 Hz, 1H), 2.61 (d, J = 16.5 Hz, 1H), 2.41 (s, 3H), 2.01 (dtd, J = 12.7, 7.1, 2.8 Hz, 1H), 1.79 – 1.65 (m, 2H), 1.56 – 1.45 (m, 1H), 1.32 (s, 3H), 1.29 (d, J = 6.7 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  151.2, 71.8, 62.4, 50.4, 37.3, 32.2, 27.6, 22.5, 13.7. **FTIR** (neat film) 2941, 2883, 1539, 1440, 1396, 1332, 1303, 1216, 1118 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 185.1112, found 185.1118.



Me<sup>T-2</sup> (3a*R*\*,6*S*\*)-3,3,6-Trimethyl-2-(methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole (3o). Following the general procedure **B** and starting from 2o (57.9 mg, 0.26 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3o as a yellowish oil (38.0 mg, 75%), d.r. (16:4). Major diastereomer: **TLC** R<sub>*f*</sub> 0.61 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H**-NMR (600 MHz, CDCl<sub>3</sub>) δ 3.61 (dd, J = 13.7, 6.8 Hz, 1H), 3.48 (t, J = 8.2 Hz, 1H), 2.39 (s, 3H), 2.01 – 1.93 (m, 1H), 1.61 – 1.55 (m, 2H), 1.36 – 1.30 (m, 1H), 1.25 (s, 3H), 1.23 (d, J = 6.8 Hz, 3H), 1.13 (s, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>) δ 158.9, 76.0, 62.0, 51.0, 32.9, 26.8, 25.8, 21.7, 20.2, 13.3. **FTIR** (neat film) 2924, 2854, 1684, 1570, 1458, 1377 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>19</sub>N<sub>2</sub>S (M+H) 199.1269, found 199.1272.



H (3a*R*\*,5*R*\*)-5-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo-[1,2-*b*]pyrazole (3p). Following the general procedure **B** and starting from 2p (61.8 mg, 0.31 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave 3p as a yellowish oil (38.2 mg, 72%), d.r. (16:4). **TLC** R<sub>f</sub> 0.32 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H**-NMR (600 MHz, CDCl<sub>3</sub>) *Major diastereomer:* δ 3.94 – 3.84 (m, 1H), 3.62 – 3.54 (m, 1H), 2.88 (dd, *J* = 16.3, 9.9 Hz, 1H), 2.79 (dd, *J* = 10.1, 10.1 Hz, 1H), 2.63 (dd, *J* = 16.3, 2.1 Hz, 1H), 2.43 (s, 3H), 2.24 – 2.12 (m, 1H), 1.92 (dt, *J* = 12.3, 6.3 Hz, 1H), 1.14 – 1.07 (m, 1H), 1.04 (d, *J* = 6.6 Hz, 3H). *Minor diastereomer:* δ 4.02 (ddd, *J* = 11.9, 9.3, 2.4 Hz, 1H), 3.68 – 3.59 (m, 2H), 3.05 – 2.96 (m, 1H), 2.60 – 2.55 (m, 1H), 2.42 (s, 3H), 2.12 – 2.01 (m, 1H), 1.63 (ddd, *J* = 12.9, 8.5, 4.6 Hz, 1H), 1.48 (dt, *J* = 12.8, 9.0 Hz, 1H), 0.97 (d, *J* = 6.6 Hz, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>) *Major diastereomer:* δ 151.2, 65.5, 62.3, 42.0, 39.6, 34.0, 18.3, 13.9. *Minor diastereomer:* δ 152.7, 64.2, 62.6, 44.9, 40.7, 31.8, 17.3. **FTIR** (neat film) 2921, 2850, 1670, 1559, 1457, 1267, 1126 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0949.



 $\begin{array}{ll} (3aS^*,4R^*)-4-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazole \\ (3q) \\ and \\ (3aS^*,4S^*)-4-Methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3H-pyrrolo[1,2-b]pyrazole \\ (3q'). Following the general procedure$ **B** $and starting from 2q (63.5 mg, 0.32 mmol), elution with CH_2Cl_2/MeOH (100:0 to 95:5) gave 3q (33.3 mg, 61%) and 3q' (8.2 mg, 15%) as yellowish oils, d.r. (16:4). \end{array}$ 



**3q: TLC**  $R_f 0.27$  (95:5  $CH_2Cl_2/MeOH$ ). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$ 3.48 (dt, J = 11.8, 7.7 Hz, 1H), 3.40 – 3.34 (m, 1H), 2.99 (td, J = 9.2, 1.8 Hz, 1H), 2.56 (dd, J = 16.1, 9.4 Hz, 1H), 2.29 – 2.23 (m, 4H), 1.64 (dtd, J = 12.6, 7.7, 5.0 Hz, 1H), 1.36 – 1.28 (m, 1H), 0.99 (ddd, J = 16.4, 12.4, 8.1 Hz, 1H), 0.59 (d, J = 6.7 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  149.0, 72.6, 54.4, 41.4, 38.0, 33.7, 17.1, 13.8. **FTIR** (neat film) 2955, 2928, 1561, 1459, 1434, 1274, 1145 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for  $C_8H_{15}N_2S$  (M+H) 171.0956, found 171.0951.



**3q': TLC**  $R_f 0.24$  (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.69 (ddd, J = 12.0, 6.7, 2.6 Hz, 1H), 3.59 (ddd, J = 9.4, 9.4, 3.0 Hz, 1H), 2.91 (ddd, J = 12.0, 10.7, 5.8 Hz, 1H), 2.52 – 2.37 (m, 2H), 2.24 (s, J = 3.1 Hz, 3H), 1.69 – 1.57 (m, 1H), 1.48 – 1.38 (m, 1H), 1.08 (dddd, J = 12.0, 10.6, 9.3, 6.7 Hz, 1H), 0.64 (d, J = 7.1 Hz, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  151.2, 67.4, 54.4, 38.4, 35.5, 33.6, 16.2, 13.8. **FTIR** (neat film) 2960, 1561, 1509, 1459 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>8</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 171.0956, found 171.0955.



(3aS\*,6aR\*)-2-(Methylthio)-4,5,6,6a,7,8-hexahydro-3*H*-cyclopenta[2,3]pyrrolo[1,2-*b*]pyrazole (3r). Following the general procedure **B** and starting from 2r (65.1 mg, 0.29 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3r as a yellowish oil (43.9 mg, 77%), d.r. (19:1). Major diastereomer: **TLC** R<sub>*f*</sub> 0.47 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H**-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.74 (dd, *J* = 12.5, 7.2 Hz, 1H), 2.93 (ddd, *J* = 12.5, 12.5, 5.9 Hz, 1H), 2.63 (d, *J* = 16.2 Hz, 1H), 2.56 (d, *J* = 16.2 Hz, 1H), 2.25 (s, 3H), 1.88 – 1.80 (m, 2H), 1.76 (ddd, *J* = 16.5, 10.7, 7.0 Hz, 1H), 1.60 (dt, *J* = 13.4, 6.5 Hz, 1H), 1.57 – 1.48 (m, 1H), 1.39 (dt, *J* = 12.3, 6.1 Hz, 1H), 1.18 – 1.07 (m, 1H), 1.06 – 0.92 (m, 2H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  151.3, 84.6, 54.4, 51.0, 50.2, 39.4, 34.7, 32.8, 27.3, 13.9. **FTIR** (neat film) 2950, 2863, 1563, 1431, 1291, 1136 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 197.1112, found 197.1109.  $(3aR^*,4aS^*,8aS^*)$ -2-(Methylthio)-3a,4,4a,5,6,7,8,8a-octahydro-3*H*-pyrazolo[1,5-*a*]indole (3s); (3aS^\*,4aS^\*,8aS^\*)-2-(Methylthio)-3a,4,4a,5,6,7,8,8a-octahydro-3*H*-pyrazolo[1,5-*a*]indole (3s'). Following the general procedure **B** and starting from 2s (58.2 mg, 0.24 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/TBME (70:30 to 60:40) gave 3s (35.3 mg, 69%) and 3s' (14.0 mg, 27%) as yellowish oils.



**3s: TLC**  $R_f$  0.50 (50:50 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$ 3.85 – 3.78 (m, 1H), 3.59 – 3.48 (m, 1H), 2.65 (dd, J = 16.4, 10.4 Hz, 1H), 2.30 (s, 3H), 2.25 (dd, J = 16.4, 3.2 Hz, 1H), 2.02 – 1.90 (m, 1H), 1.81 – 1.72 (m, 1H), 1.60 – 1.56 (m, 1H), 1.54 – 1.44 (m, 2H), 1.37 – 1.43 (m, 1H), 1.37 – 1.28 (m, 1H), 1.25 – 1.10 (m, 3H), 1.06 – 0.96 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  151.3, 65.9, 62.8, 44.5, 36.8, 36. 7, 28.6, 26.8, 24.0, 22.4, 14.2. **FTIR** (neat film) 2926, 2854, 1563, 1447, 1298, 1268, 1137 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>19</sub>N<sub>2</sub>S (M+H) 211.1269, found 211.1267.



**3s': TLC**  $R_f$  0.28 (50:50 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.69 – 3.61 (m, 1H), 3.30 (dd, J = 11.9, 5.9 Hz, 1H), 2.57 (dd, J = 16.3, 10.4 Hz, 1H), 2.28 (s, 3H), 2.22 (dd, J = 16.3, 4.2 Hz, 1H), 2.09 – 1.99 (m, 1H), 1.89 – 1.82 (m, 2H), 1.82 – 1.73 (m, 1H), 1.68 – 1.57 (m, 1H), 1.47 – 1.29 (m, 3H), 1.20 – 1.11 (m, 2H), 1.04 – 0.96 (m, 1H). <sup>13</sup>C-**NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  149.6, 64.4, 62.5, 44.2, 39.4, 37.9, 29.9, 26.9, 24.3, 24.2, 14.1. **FTIR** (neat film) 2925, 2854, 1561, 1447, 1293, 1264, 1158, 1127 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>19</sub>N<sub>2</sub>S (M+H) 211.1269, found 211.1263.



HMBC **G** (3a*S*,8a*S*)-2-(Methylthio)-3,3a,4,6,7,8,8a,9-octahydropyrazolo[1,5-*d*]pyrrolo[1,2-*a*]pyrazine (3t). Following the general procedure **B** and starting from 2t (71.2 mg, 0.30 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (95:5 to 85:15) gave 3t as a yellowish oil (39.3 mg, 63%, 98% estimated purity by NMR). [ $\alpha$ ]<sup>18</sup><sub>D</sub>-92.6° (c 0.53, CHCl<sub>3</sub>). **TLC** R<sub>f</sub> 0.38 (90:10 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 4.07 (dd, *J* = 12.8, 2.9 Hz, 1H), 3.58 – 3.50 (m, 1H), 2.97 (dd, *J* = 12.8, 10.5 Hz, 1H), 2.79 (td, *J* = 8.7, 1.9 Hz, 1H), 2.51 (dd, *J* = 15.2, 8.1 Hz, 1H), 2.30 – 2.25 (m, 4H), 2.06 – 1.97 (m, 1H), 1.96 – 1.88 (m, 2H), 1.77 (dt, *J* = 8.7, 8.7 Hz, 1H), 1.60 – 1.50 (m, 1H), 1.50 – 1.41 (m, 1H), 1.39 – 1.29 (m, 1H), 1.17 – 1.10 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 149.0, 61.5, 60.4, 56.4, 54.4, 53.4, 41.4, 28.0, 21.6, 14.0. **FTIR** (neat film) 2961, 2795, 1555, 1428, 1287, 1169 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>10</sub>H<sub>18</sub>N<sub>3</sub>S (M+H) 212.1221, found 212.1219.



(3aR, 9aR)-2-(Methylthio)-3a,4,6,7,8,9,9a,10-octahydro-3H-

**pyrazolo**[1,5-*d*]**pyrido**[1,2-*a*]**pyrazine** (**3u**). Following the general procedure **B** and starting from **2u** (64.6 mg, 0.26 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 90:10) gave **3u** as a yellowish oil (35.0 mg, 61%, 99% estimated purity by NMR). **TLC** R<sub>*f*</sub> 0.21 (90:10 CH<sub>2</sub>Cl<sub>2</sub>/MeOH).  $[\alpha]_{D}^{18}$ +70.4° (c 0.75, CHCl<sub>3</sub>). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.90 – 3.80 (m, 1H), 3.38 – 3.32 (m, 1H), 3.30 (dd, *J* = 14.4, 4.1 Hz, 1H), 2.98 (dd, *J* = 13.9, 11.9 Hz, 1H), 2.95 – 2.87 (m, 1H), 2.66 (d, *J* = 14.4 Hz, 1H), 2.63 – 2.56 (m, 1H), 2.43 (dd, *J* = 15.2, 8.0 Hz, 1H), 2.27 (s, 3H), 2.04 – 1.97 (m, 1H), 1.82 (dd, *J* = 15.2, 4.4 Hz, 1H), 1.79 – 1.70 (m, 2H), 1.58 – 1.50 (m, 1H), 1.47 – 1.34 (m, 3H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  147.5, 56.9, 56.7, 55.6, 53.3, 49.1, 41.6, 33.8, 32.9, 27.2, 14.1. **FTIR** (neat film) 2926, 2853, 1433, 1367, 1292, 1261, 1066 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>20</sub>N<sub>3</sub>S (M+H) 226.1378, found 226.1380.



(3aR,10aS)-3a-Methyl-2-(methylthio)-3,3a,4,10,10a,11-

**hexahydropyrazolo**[1',5':4,5]**pyrazino**[1,2-*a*]**indole** (3**v**). Following the general procedure **B** and starting from 2**v** (39.7 mg, 0.13 mmol), elution with hexane/EtOAc (90:10 to 80:20) gave 3**v** as a yellowish oil (15.1 mg, 42%). **TLC** R<sub>*f*</sub> 0.38 (75:25 hexane/EtOAc).  $[\alpha]_D^{19}$ -30.8° (c 0.37, CHCl<sub>3</sub>). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.11 (t, *J* = 7.7 Hz, 1H), 6.97 (d, *J* = 7.2 Hz, 1H), 6.77 – 6.73 (m, 1H), 6.31 (d, *J* = 7.7 Hz, 1H), 3.77 (dd, *J* = 13.7, 3.0 Hz, 1H), 3.31 – 3.25 (m, 1H), 3.10 (dd, *J* = 13.7, 11.2 Hz, 1H), 2.64 (d, *J* = 11.9 Hz, 1H), 2.59 (d, *J* = 11.9 Hz, 1H), 2.48 (dd, *J* = 14.8, 7.6 Hz, 1H), 2.39 (d, *J* = 15.3 Hz, 1H), 2.25 (s, 3H), 2.21 – 2.07 (m, 1H), 1.92 (d, *J* = 15.3 Hz, 1H), 1.26 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  152.5, 148.3, 129.5, 127.9, 125.4, 118.9, 106.9, 65.1, 61.0, 52.0, 48.8, 48.7, 32.9, 21.9, 13.8. **FTIR** (neat film) 2924, 2810, 1607, 1482, 1294, 1233 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub>S (M+H) 274.1378, found 274.1382.

MeS 2-(Methylthio)-3a,4,6,7-tetrahydro-3*H*-pyrazolo[5,1-*c*][1,4]oxazine (3w). Following the general procedure **B** and starting from 2w (69.0 mg, 0.35 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3w as a yellowish oil (41.5 mg, 70%, 98% estimated purity by NMR). **TLC** R<sub>*f*</sub> 0.47 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H**-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  3.51 (dd, *J* = 13.5, 2.1 Hz, 1H), 3.45 (ddd, *J* = 11.5, 11.5, 2.4 Hz, 1H), 3.39 (dd, *J* = 11.5, 3.9 Hz, 1H), 3.35 – 3.27 (m, 1H), 3.23 – 3.14 (m, 1H), 3.12 (dd, *J* = 10.5, 5.4 Hz, 2H), 2.28 (dd, *J* = 15.5, 8.0 Hz, 1H), 2.22 (s, 3H), 1.66 (dd, *J* = 15.5, 4.1 Hz, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  150.6, 66.5, 65.5, 61.1, 51.0, 39.9, 14.0. **FTIR** (neat film) 2924, 2854, 1668, 1457, 1261, 1107 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>13</sub>N<sub>2</sub>OS (M+H) 173.0749, found 173.0742.



Figure SI 1. Aromatization via hemiaminal cleavage.

<sup>MeS</sup>  $\stackrel{\circ}{\longrightarrow}$  **2-(3-(Methylthio)-1***H***-pyrazol-1-yl)ethanol (7)**. Following the general procedure **B** and starting from **2x** (66.9 mg, 0.36 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (90:10 to 80:20) gave **8** as a yellowish oil (40.9 mg, 72%, 97% estimated purity by NMR). **TLC** R<sub>f</sub> 0.41 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  6.81 (d, J = 1.9 Hz, 1H), 5.99 (d, J = 1.9 Hz, 1H), 3.68 – 3.54 (m, 4H), 2.25 (s, 3H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  148.0, 132.1, 105.7, 62.0, 54.4, 16.0. **FTIR** (neat film) 3401, 2916, 1652, 1495, 1416, 1134 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>6</sub>H<sub>11</sub>N<sub>2</sub>OS (M+H) 159.0592, found 159.0594.



 $(3S^*, 3aR^*) \hbox{-} 3- Methoxy \hbox{-} 3a-methyl \hbox{-} 2-(methylthio) \hbox{-} 3a, 4, 5, 6-tetrahydro \hbox{-} 3H-tetrahydro \hbox{-} 3H-tetra$ 

**pyrrolo**[1,2-*b*]**pyrazole** (3**y**). Following the general procedure **B** and starting from Z-2**y** (46.2 mg, 0.20 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave **3y** as a yellowish oil (28.4 mg, 70%), d.r. (18:2). Major diastereomer: **TLC** R<sub>*f*</sub> 0.58 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.03 (s, 1H), 3.63 – 3.53 (m, 1H), 3.08 (s, 3H), 3.01 (ddd, J = 12.2, 9.5, 7.0 Hz, 1H), 2.28 (ddd, J = 6.9, 6.5, 3.5 Hz, 1H), 2.25 (s, 3H), 1.64 – 1.54 (m, 1H), 1.48 – 1.36 (m, 1H), 1.17 (s, 3H), 1.09 – 0.99 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  153.4, 94.7, 76.5, 59.2, 55.2, 30.1, 27.2, 25.6, 13.6. **FTIR** (neat film) 2923, 2851, 1681, 1456, 1204, 1134 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>OS (M+H) 201.1062, found 201.1063.



MeO\_NOESY (3*R*\*,3a*R*\*)-3-Methoxy-3a-methyl-2-(methylthio)-3a,4,5,6-tetrahydro-3*H*-pyrrolo[1,2-*b*]pyrazole (3z). Following the general procedure **B** and starting from *E*-2z (54.8 mg, 0.24 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (80:20 to 70:30) gave 3z as a yellowish oil (31.5 mg, 66%), d.r. (15:5). Major diastereomer: **TLC** R<sub>f</sub> 0.62 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>**H**-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 3.95 (s, 1H), 3.71 – 3.63 (m, 1H), 3.34 (s, 3H), 3.01 (ddd, J = 12.9, 9.3, 6.5 Hz, 1H), 2.21 (s, 3H), 1.55 – 1.42 (m, 1H), 1.37 – 1.25 (m, 2H), 1.18 (s, 3H), 1.17 – 1.13 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 151.1, 91.8, 75.6, 57.4, 53.2, 35.5, 24.5, 19.0, 13.9. **FTIR** (neat film) 2929, 1681, 1450, 1203, 1110 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>9</sub>H<sub>17</sub>N<sub>2</sub>OS (M+H) 201.1062, found 201.1066.



**NOESY** (3*S*\*,3*aR*\*,6*aR*\*)-3-Methoxy-2-(methylthio)-4,5,6,6a,7,8-hexahydro-3*H*-cyclopenta[2,3]pyrrolo[1,2-*b*]pyrazole (3aa). Following the general procedure **B** and starting from *Z*-2aa (66.0 mg, 0.26 mmol), elution with hexane/EtOAc (60:40 to 50:50) gave 3aa as a yellowish oil (36.4 mg, 62%), d.r. > (20:1). **TLC** R<sub>*f*</sub> 0.27 (50:50 hexane/EtOAc). <sup>1</sup>**H**-**NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.22 (s, 1H), 3.66 (dd, *J* = 12.5, 7.3 Hz, 1H), 3.17 (s, 3H), 3.03 – 2.89 (m, 2H), 2.25 (s, 3H), 2.01 (dt, *J* = 13.7, 7.0 Hz, 1H), 1.85 – 1.77 (m, 1H), 1.73 – 1.63 (m, 2H), 1.47 – 1.32 (m, 2H), 1.17 – 1.08 (m, 2H). <sup>13</sup>**C**-**NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  154.1, 94.9, 88.1, 60.0, 55.8, 40.9, 39.9, 34. 7, 33.0, 27.0, 13.6. **FTIR** (neat film) 2952, 2929, 2864, 1681, 1453, 1111 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>19</sub>N<sub>2</sub>OS (M+H) 227.1218, found 227.1218.



MeO (3*R*\*,3a*R*\*,6a*R*\*)-3-Methoxy-2-(methylthio)-4,5,6,6a,7,8-hexahydro-3*H*cyclopenta[2,3]pyrrolo[1,2-*b*]pyrazole (3bb). Following the general procedure **B** and starting from *E*-2bb (64.6 mg, 0.25 mmol), elution with hexane/EtOAc (70:30 to 60:40) gave 3bb as a yellowish oil (24.6 mg, 43%, 96% estimated purity by NMR), d.r. (>20:1). TLC R<sub>f</sub> 0.45 (50:50 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  4.20 (s, 1H), 3.71 (dd, *J* = 12.6, 7.4 Hz, 1H), 3.32 (s, 3H), 2.91 (ddd, *J* = 12.6, 12.6, 6.3 Hz, 1H), 2.33 – 2.25 (m, 1H), 2.24 (s, 3H), 1.88 – 1.78 (m, 1H), 1.69 – 1.49 (m, 3H), 1.48 – 1.39 (m, 1H), 1.27 – 1.17 (m, 1H), 1.03 – 0.95 (m, 1H), 0.91 (dd, *J* = 12.5, 6.3 Hz, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  151.8, 90.6, 87.0, 55.3, 53.9, 47.9, 34.2, 32.1, 30.3, 27.2, 13.7. FTIR (neat film) 2924, 2853, 1734, 1676, 1445, cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>11</sub>H<sub>19</sub>N<sub>2</sub>OS (M+H) 227.1218, found 227.1211.

MeS 2-(Methylthio)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazole (8). Following the general procedure **B** and starting from 2cc (56.2 mg, 0.31 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (90:10 to 80:20) gave **9** as a yellowish oil (9.2 mg, 19%). **TLC** R<sub>f</sub> 0.49 (25:75 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.94 (s, 1H), 4.11 (t, *J* = 7.2 Hz, 2H), 2.86 (t, *J* = 7.3 Hz, 2H), 2.56 (tt, *J* = 7.3, 7.2 Hz, 2H), 2.48 (s, 3H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  150.5, 147.0, 99.6, 47.9, 25.8, 23.2, 16.9. **FTIR** (neat film) 2955, 2924, 1655, 1531, 1456, 1359, 1315 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>7</sub>H<sub>11</sub>N<sub>2</sub>S (M+H) 155.0643, found 155.0642.

Eto **Ethyl 3a,4,5,6-tetrahydro-3H-pyrrolo**[1,2-*b*]**pyrazole-2-carboxylate** (14). Following the general procedure **B** and starting from 13 (52.0 mg, 0.25 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave 14 as a yellowish oil (30.8 mg, 68%, 96% estimated purity by NMR). **TLC** R<sub>f</sub> 0.68 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 4.09 (q, J = 7.1 Hz, 2H), 3.62 – 3.53 (m, 1H), 3.33 – 3.25 (m, 1H), 2.95 (ddd, J = 12.0, 7.7, 7.7, Hz, 1H), 2.71 – 2.68 (m, 2H), 1.27 – 1.18 (m, 1H), 1.14 (dddd, J = 12.8, 7.7, 7.7, 5.2 Hz, 1H), 1.10 – 1.03 (m, 1H), 1.01 (t, J = 7.1 Hz, 3H), 0.90 – 0.81 (m, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 162.9, 143.8, 65.1, 60.7, 53.0, 38.2, 30.1, 23.9, 14.3. **FTIR** (neat film) 2964, 1704, 1561, 1380, 1251, 1135 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>9</sub>H<sub>15</sub>N<sub>2</sub>O<sub>2</sub> (M+H) 183.1134, found 183.1139.







**Figure SI 2. Isomerization of 2h under the reaction conditions**. Stacked CD<sub>3</sub>CN spectra of a) **2h**, b) **2h** after 300 min of reaction time and c) **2g**.



**Figure SI 3. Isomerization of 2aa and 2bb under the reaction conditions**. Stacked CD<sub>3</sub>CN spectra of a) **2aa**, b) **2aa** after 300 min of reaction time, c) **2bb**, and d) **2bb** after 300 min of reaction time.

# E. UV Absorbance Spectra of Tetrazole Substrates.

Substrates were dissolved in EtOH at various concentrations and UV spectra were recorded. All spectra in Figure 2 of the manuscript were recorded at 1.25 mM concentration for consistency.  $\epsilon_{254}$  values (Avg\*) were determined based on sample concentrations resulting in  $0.1 < A_{254} < 3.0$ .

Compound	[mM]	150	75.0	25.0	12.5	2.50	1.25	0.500	0.250	0.125	0.050	Avg*
2a	A <sub>254</sub>					3.45	2.86	1.26	0.688			
(X = SMe)	E254					1380	2290	2520	2750			2520
5	A <sub>254</sub>					3.58	3.32	1.52	0.798	0.376		
(X = SBn)	E254					1430	2650	3040	3190	3010		3080
11	A <sub>254</sub>	0.719	0.374			0.0495	0.0494					
(X = Me)	E254	4.79	4.99			19.8	39.5					4.89
13	A <sub>254</sub>			1.60	0.785	0.195	0.107					
$(X = CO_2Et)$	E254			63.8	62.8	78.0	85.8					72.6
15	A <sub>254</sub>					3.72	3.51	3.01	2.09	1.09	0.444	
(X = Ph)	E254					1490	2810	6030	8360	8750	8880	8670

 Table 1. UV Absorbance Spectra of Tetrazole Substrates















# F. Further Functionalization of Pyrazoline Scaffolds: Synthesis of 8, 16, 17, 18.

**2-Phenyl-3a,4,5,6-tetrahydro-3***H***-pyrrolo[1,2-***b***]pyrazole (16). Copper (I) 3-methylsalicylate (CuMeSal) (110.3 mg, 0.51 mmol) and Pd(Ph<sub>3</sub>P)<sub>4</sub> (27.0 mg, 0.02 mmol, 10 mol%) were added to a degassed solution of <b>3a** (36.5 mg, 0.23 mmol) and phenylboronic acid (62.7 mg, 0.51 mmol) in THF (5 mL) under Ar. The reaction mixture was heated to 80 °C for 13 h. Then, the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography and elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (90:10 to 80:20) gave **16** as a yellowish oil (33.5 mg, 77%). The spectroscopic data is identical to the product described above.

#### HCI H

Tetrahydro-1*H*-pyrrolo[1,2-*b*]pyrazol-2(3*H*)-one hydrochloride (17). A solution of 3a (23.6 mg, 0.15 mmol) in 4M HCl (2 mL) was heated to 100 °C for 22 h. The solvent was removed under reduced pressure to give 17 as its hydrochloride salt (18.0 mg, 96%, 97% estimated purity by NMR).

<sup>1</sup>**H-NMR** (600 MHz, CD<sub>3</sub>OD) δ 4.84 – 4.74 (m, 1H), 3.79 (dt, J = 12.1, 7.5 Hz, 1H), 3.47 (dt, J = 12.1, 6.1 Hz, 1H), 3.12 (dd, J = 17.7, 9.9 Hz, 1H), 2.74 (dd, J = 17.7, 5.2 Hz, 1H), 2.46 – 2.38 (m, 1H), 2.29 (dt, J = 14.1, 7.2 Hz, 1H), 2.19 – 2.11 (m, 1H), 2.11 – 2.00 (m, 1H). <sup>13</sup>**C-NMR** (151 MHz, CD<sub>3</sub>OD) δ 174.3, 67.6, 59.9, 36.1, 32.2, 24.5. MS (ESI) *m/z*: 127 (M+H, 100), 162 (M+HCl, 34). **HRMS** (ESI) *m/z*: Calcd for C<sub>6</sub>H<sub>11</sub>N<sub>2</sub>O (M+H) 127.0871, found 127.0870.

Confirmation of the structural assignment was achieved by liberation of the free base upon column chromatography on silica gel and elution with  $CH_2Cl_2/MeOH/NH_4OH$  (90:10:0.6). The resulting spectroscopic data matches that reported in literature:<sup>24</sup>

**TLC**  $R_f 0.28$  (90:10:0.6 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>4</sub>OH). <sup>1</sup>**H-NMR** (CDCl<sub>3</sub>, 600 MHz) 4.07 – 4.04 (m, 1H), 3.10 (td, J = 11.0, 6.3 Hz, 1H), 2.86 (td, J = 11.0, 6.7 Hz, 1H), 2.62 (dd, J = 17.1, 9.3 Hz, 1H), 2.43 (dd, J = 17.1, 8.0 Hz, 1H), 2.11 – 1.99 (m, 2H), 1.82 – 1.74 (m, 2H). <sup>13</sup>C-NMR (CDCl<sub>3</sub>, 150 MHz) 174.5, 62.0, 57.9, 37.5, 31.2, 23.7.

MeS 2-(Methylthio)-5,6-dihydro-4*H*-pyrrolo[1,2-*b*]pyrazole (8). A mixture of 3a (24.9 mg, 0.16 mmol) and DDQ (43.4 mg, 0.19 mmol) in dry CHCl<sub>3</sub> (2 mL) was purged with Ar in a sealed vessel and microwaved at 120 °C for 10 min. Purification by column chromatography on silica gel eluting with hexane/EtOAc (70:30 to 60:40) gave 8 as a yellowish oil (20.3 mg, 83%). Spectroscopic data matches the previously described.

**Hexahydro-1***H***-pyrrolo**[1,2-*b*]**pyrazole** (18). A 15 mL flame dried schlenk tube was charged with 3a (24.8 mg, 0.16 mmol) and AgOTf (61.2 mg, 0.24 mmol). The residue was azeotroped, and dissolved with dry THF (3 mL). The reaction mixture appeared to be a white precipitate and it was stirred at r.t. for 10 min. Then, LiAlH<sub>4</sub> (30.1 mg, 0.79 mmol) was added, and the reaction mixture immediately turned into a black precipitate. The suspension was stirred at r.t. for 1 h. Then, H<sub>2</sub>O (0.25 mL) was added dropwise, followed by NaOH 15% aq. sol (0.25

mL) and additional H<sub>2</sub>O (0.25 mL) and stirred vigorously for 10 min. Then MgSO<sub>4</sub> was added, the solvents were filtered off and the solid residue was washed  $3x \text{ CH}_2\text{Cl}_2$ . 12 N HCl (1.5 mL) was added to the organic solution, and the resulting biphasic white suspension was evaporated under reduced pressure, and then lyophilized. The semisolid residue was triturated for 5 min under sonication with MeCN-benzene (50:50, 3 mL) and the resulting suspension was kept overnight at the freezer. Then, the clear supernatant solution was discarded and the solid residue was dried under reduced pressure to yield hexahydro-1H-pyrrolo[1,2-*b*]pyrazole **18** hydrochloride as a semisolid (21.2 mg, 90%, 98% estimated purity by NMR).

**TLC** (alumina)  $R_f 0.32$  (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H-NMR** (500 MHz, CDCl<sub>3</sub>)  $\delta$  4.44 (tt, J = 8.5, 5.5 Hz, 1H), 3.77 – 3.65 (m, 1H), 3.35 (dt, J = 12.3, 6.3 Hz, 1H), 3.27 – 3.15 (m, 2H), 2.49 – 2.36 (m, 1H), 2.34 – 2.22 (m, 1H), 2.14 (tt, J = 13.4, 6.8 Hz, 1H), 2.07 – 1.87 (m, 2H), 1.79 (ddd, J = 13.0, 6.6, 6.4 Hz, 1H). <sup>13</sup>C-NMR (126 MHz, CDCl<sub>3</sub>)  $\delta$  68.8, 57.7, 47.3, 33.0, 30.5, 23.8. **FTIR** (neat film) 3356, 2922, 2851, 1260, 1110 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>6</sub>H<sub>13</sub>N<sub>2</sub> (M+H) 113.1079, found 113.1077.

#### G. Total Syntheses of (±)-Newbouldine and Withasomnine 19-28.

OH

(Z)-5-Phenylpent-4-en-1-ol. <sup>*t*</sup>BuOK (1.004 g, 8.94 mmol) was added to a 0 °C cooled suspension of [3-(ethoxycarbonyl)propyl]triphenylphosphonium bromide **28** (4.090 g, 8.94 mmol) in anhydrous THF (30 mL). The resulting orange colored solution was allowed to warm to r.t. and stirred for 30 min. Then benzaldehyde (695  $\mu$ L, 6.88 mmol) was added dropwise and the reaction mixture was stirred for additional 1 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (95:5 to 85:15) gave ethyl (Z)-5-phenylpent-4-enoate (846.4 mg, 60%).<sup>25</sup> LiAlH<sub>4</sub> (181.8 mg, 4.78 mmol) was added to a 0 °C cooled solution of ethyl (Z)-5-phenylpent-4-enoate (751.0 g, 3.68 mmol) in THF (35 mL). The suspension was allowed to warm to r.t. and stirred for 1 h. Then, H<sub>2</sub>O (0.5 mL) was added dropwise, followed by 15% aq. NaOH (0.5 mL), and H<sub>2</sub>O (1.5 mL). The resulting mixture was stirred for 15 min. The resulting suspension was filtered through a pad of Celite, and the pad was washed with methanol. The combined organic fractions were concentrated under reduced pressure to give (Z)-5-phenylpent-4-en-1-ol (596 mg, quant.) as a colorless oil.<sup>25a, 26</sup>



(Z)-5-(Methylthio)-2-(5-phenylpent-4-enyl)-2H-tetrazole (Z-22).

Following the general procedure **A** and starting from (*Z*)-5-phenylpent-4-en-1-ol (305.1 mg, 1.88 mmol, 1.1 equiv.), elution with hexane/EtOAc (90:10 to 80:20) gave **Z-22** (376.7 mg, 85%, 94:6 *Z/E*) as a colorless oil. **TLC** R<sub>*f*</sub> 0.60 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.18 – 7.13 (m, 2H), 7.11 – 7.07 (m, 2H), 7.07 – 7.03 (m, 1H), 6.33 (d, *J* = 11.6 Hz, 1H), 5.23 (dt, *J* = 11.6, 7.3 Hz, 1H), 3.78 (t, *J* = 7.3 Hz, 2H), 2.26 (s, 3H), 1.99 – 1.91 (m, 2H), 1.60 – 1.49 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.6, 137.9, 131.0, 130.7, 129.4, 128.9, 127.5, 52.6, 29.6, 25.8, 14.3. **FTIR** (neat film) 2928, 1724, 1400, 1376, 1177, 1137, 1054 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 261.1174, found 261.1175.

#### eS N N N N

 $-\frac{1}{2}$  (E)-5-(Methylthio)-2-(5-phenylpent-4-enyl)-2H-tetrazole (E-22).

Following the general procedure **A** and starting from (*E*)-5-phenylpent-4-en-1-ol<sup>27</sup> (1.1775 g, 7.26 mmol, 1.1 equiv.), elution with hexane/EtOAc (85:15 to 75:25) gave *E*-22 (1.4259 g, 83%, >99:1 *E/Z*) as a colorless oil. **TLC**  $R_f$  0.55 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz,  $C_6D_6$ )  $\delta$  7.24 – 7.17 (m, 2H), 7.14 (dd, *J* = 9.9, 8.5 Hz, 2H), 7.09 – 7.04 (m, 1H), 6.16 (d, *J* = 15.8 Hz, 1H), 5.82 – 5.64 (m, 1H), 3.96 – 3.78 (m, 2H), 2.29 (s, 3H), 1.80 – 1.68 (m, 2H), 1.62 – 1.50 (m, 2H). <sup>13</sup>**C-NMR** (151 MHz,  $C_6D_6$ )  $\delta$  165.7, 138.1, 132.2, 129.2, 128.7, 127.8, 126.8, 52.5, 30.0, 29.0, 14.3. **FTIR** (neat film) 2933, 1723, 1496, 1401, 1364, 1288, 1055 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 261.1174, found 261.1166.



(*E*)-2-(5-Phenylpent-4-enyl)-2*H*-tetrazole. A 0.54 M MeCN solution of 1*H*-tetrazole (4.21 mL, 2.28 mmol) and diisopropyl azodicarboxylate (0.740 mL, 3.76 mmol) were added to a stirred solution of PPh<sub>3</sub> (985.3 mg, 3.76 mmol) and (*E*)-5-phenylpent-4-en-1-ol<sup>27</sup> (406.3 mg, 2.51 mmol) in THF (20 mL) at r.t. under Ar. The resulting mixture was heated to 80 °C for 16 h. Then, the solvent was evaporated under reduced pressure, and the residue was purified by silica gel chromatography. Elution with hexane/EtOAc (90:10 to 80:20) gave the entitled product (402.3 mg mg, 75%) as a colorless oil. **TLC** R<sub>*f*</sub> 0.34 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  8.51 (s, 1H), 7.34 (dd, *J* = 8.2, 1.1 Hz, 2H), 7.32 – 7.28 (m, 2H), 7.24 – 7.19 (m, 1H), 6.43 (d, *J* = 15.8 Hz, 1H), 6.16 (dt, *J* = 15.8, 6.8 Hz, 1H), 4.70 (t, *J* = 6.8 Hz, 2H), 2.27 (dd, *J* = 14.2, 6.8 Hz, 2H), 2.25 – 2.17 (m, 2H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  152.8, 137.1, 131.8, 128.5, 127.7, 127.3, 126.0, 52.3, 29.5, 28.8. **FTIR** (neat film) 3140, 3026, 2935, 1598, 1493, 1446, 1359, 1282, 1131, 1008 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>12</sub>H<sub>15</sub>N<sub>4</sub> (M+H) 215.1297, found 215.1299.





5-(Methylthio)-2-(5-phenylpent-4-ynyl)-2*H*-tetrazole (27). Following the general procedure **A** and starting from 5-phenylpent-4-yn-1-ol<sup>4b, 28</sup> (429.2 mg, 2.68 mmol, 1.1 equiv.), elution with hexane/EtOAc (80:20 to 70:30) gave **26** (491.6 mg, 78%) as a colorless oil. **TLC**  $R_f$  0.53 (75:25 hexane/EtOAc). <sup>1</sup>**H-NMR** (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.45 – 7.41 (m, 2H), 7.02 – 6.96 (m, 3H), 4.02 (t, *J* = 6.8 Hz, 2H), 2.26 (s, 3H), 1.94 (t, *J* = 6.9 Hz, 2H), 1.65 (tt, *J* = 6.9, 6.8 Hz, 2H). <sup>13</sup>**C-NMR** (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.8, 132.3, 128.9, 128.5, 124.5, 88.2, 82.8, 52.1, 28.4, 17.0, 14.3. **FTIR** (neat film) 3055, 2932, 2230, 1598, 1490, 1400, 1286, 1070, 757 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>4</sub>S (M+H) 259.1017, found 259.1014.



(3S\*,3aR\*)-2-(Methylthio)-3-phenyl-3a,4,5,6-tetrahydro-3H-pyrrolo-

**[1,2-b]pyrazole** (*anti-23*). Following the general procedure **B** with 8 h irradiation time and starting from **Z-22** (271.9 mg, 1.04 mmol), elution with hexane/EtOAc (50:50 to 20:80) gave *anti-23* (104.9 mg, 43%), and the C3 epimer *syn-23* (67.4 mg 28%) as yellowish oils. *Anti-22*: **TLC** R<sub>f</sub> 0.26 (50:50 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.13 – 7.09 (m, 2H), 7.08 (d, J = 6.7 Hz, 2H), 7.04 (t, J = 7.1 Hz, 1H), 4.29 (d, J = 10.0 Hz, 1H), 3.83 (ddd, J = 10.0, 8.3, 7.2 Hz, 1H), 3.70 (ddd, J = 12.0, 7.2, 4.5 Hz, 1H), 3.10 (ddd, J = 12.0, 8.0, 7.2 Hz, 1H), 2.28 (s, 3H), 1.44 (ddd, J = 15.4, 12.0, 7.2 Hz, 1H), 1.36 (td, J = 13.0, 6.5 Hz, 1H), 1.26 – 1.15 (m, 1H), 0.83 (ddd, J = 15.4, 13.0, 7.5 Hz, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  152.6, 136.3, 130.5, 128.8,

127.8, 71.0, 59.4, 56.1, 26.4, 24.9, 14.4. **FTIR** (neat film) 3029, 2926, 2869, 1603, 1550, 1494, 1453, 1238, 1155 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for  $C_{13}H_{17}N_2S$  (M+H) 233.1112, found 233.1110.



**NOESY** (*3R*\*,3*aR*\*)-2-(Methylthio)-3-phenyl-3a,4,5,6-tetrahydro-3*H*-pyrrolo-[1,2-*b*]pyrazole (*syn*-23). Following the general procedure **B** with 16 h irradiation time and starting from *E*-22 (100.2 mg, 0.39 mmol), elution with hexane/EtOAc (50:50 to 40:60) gave *syn*-23 as a yellowish oil (65.3 mg, 73%). **TLC** R<sub>f</sub> 0.43 (50:50 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  7.34 (bd, *J* = 8.0 Hz, 2H), 7.15 – 7.11 (m, 2H), 7.04 (dd, *J* = 7.0, 2.4 Hz, 1H), 3.79 – 3.68 (m, 2H), 3.57 (td, *J* = 6.8, 3.4 Hz, 1H), 2.95 (ddd, *J* = 12.2, 8.8, 6.8 Hz, 1H), 2.19 (s, 3H), 1.58 – 1.40 (m, 2H), 1.30 – 1.18 (m, 2H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  155.0, 141.6, 129.4, 128.3, 127.8, 74.7, 64.1, 55.1, 31.7, 24.6, 14.2. **FTIR** (neat film) 3061, 2928, 2869, 1602, 1557, 1494, 1453, 1175, 1121 cm<sup>-1</sup>. **HRMS** (ESI) *m*/*z*: Calcd for C<sub>13</sub>H<sub>17</sub>N<sub>2</sub>S (M+H) 233.1112, found 233.1107.



(3*R*\*,3a*R*\*)-3-Phenyltetrahydro-1*H*-pyrrolo[1,2-*b*]pyrazol-2(3*H*)-one (24). 12 M HCl (20 mL) was added to a solution of *syn*-23 (135.1 mg, 0.58 mmol) in THF (1 mL). The resulting solution was heated to 100 °C for 24 h. Then, the solvent was removed under reduced pressure. The residue was purified by basic alumina gel chromatography and elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave 24 (94.3 mg, 80%) as a pinkish solid. m.p. (MeOH) 120.0 – 121.4 °C. **Basic alumina TLC** R<sub>*f*</sub> 0.47 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H**-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$ 8.06 (bs, 1H), 7.40 – 7.34 (m, 2H), 7.31 – 7.25 (m, 3H), 4.10 – 4.02 (m, 1H), 3.70 (d, *J* = 9.6 Hz, 1H), 3.31 – 3.21 (m, 1H), 3.01 – 2.88 (m, 1H), 2.17 – 2.06 (m, 2H), 1.96 – 1.86 (m, 2H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  175.2, 137.2, 128.9, 128.5, 127.5, 71.8, 57.7, 54.0, 29.1, 23.8. **FTIR** (neat film) 3186, 3063, 2968, 1690, 1497, 1454, 1293, 1071 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub>O (M+H) 203.1184, found 203.1180.



(±)-Newbouldine (19). Cp<sub>2</sub>ZrHCl (48.1 mg, 0.19 mmol) was added in one solid portion to a -20 °C solution of 24 (13.2 mg, 0.07 mmol) in THF (5 mL). After stirring 2 h at this temperature, silica gel was added to the reaction mixture and the solvent was removed under reduced pressure. The residue was purified by silica gel chromatography and elution with CHCl<sub>3</sub>/MeOH (100:0 to 95:5) gave (±)-newbouldine (19) (10.2 mg, 84%) as a yellowish oil. TLC R<sub>f</sub> 0.32 (95:5 CHCl<sub>3</sub>/MeOH). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.33 – 7.29 (m, 2H), 7.26 – 7.21 (m, 3H), 6.85 (bs, 1H), 3.99 (bs, 1H), 3.72 – 3.65 (m, 2H), 3.23 – 3.17 (m, 1H), 2.03 – 1.95

(m, 1H), 1.76 - 1.67 (m, 2H), 1.65 - 1.54 (m, 1H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  147.1, 140.3, 128.9, 127.3, 127.2, 71.2, 60.9, 53.5, 31.2, 23.7. HRMS (ESI) *m/z*: Calcd for C<sub>12</sub>H<sub>15</sub>N<sub>2</sub> (M+H) 187.1235, found 187.1228. Spectroscopic data identical to the reported in literature.<sup>29</sup>

**2-(Methylthio)-3-phenyl-5,6-dihydro-4***H***-pyrrolo[1,2-***b***]pyrazole (25). A mixture of** *syn-23* **(9.0 mg, 0.04 mmol) and DDQ (10.6 mg, 0.05 mmol) in dry CHCl<sub>3</sub> (0.5 mL) was purged with Ar in a sealed vessel and microwaved at 120 °C for 10 min. Purification by column chromatography on silica gel eluting with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (95:5 to 85:15) gave <b>25** (8.0 mg, 90%) as a yellowish oil. **TLC** R<sub>*f*</sub> 0.75 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>**H-NMR** (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.53 (dd, *J* = 8.3, 1.1 Hz, 2H), 7.41 – 7.36 (m, 2H), 7.25 – 7.21 (m, 1H), 4.17 (t, *J* = 7.3 Hz, 2H), 3.07 – 2.97 (m, 2H), 2.68 – 2.56 (m, 2H), 2.51 (s, 3H). <sup>13</sup>**C-NMR** (151 MHz, CDCl<sub>3</sub>)  $\delta$  147.5, 144.8, 133.0, 128.5, 127.2, 126.0, 114.7, 48.1, 25.8, 24.0, 16.3. **FTIR** (neat film) 2958, 2924, 1602, 1574, 1384, 1003 cm<sup>-1</sup>. **HRMS** (ESI) *m/z*: Calcd for C<sub>13</sub>H<sub>15</sub>N<sub>2</sub>S (M+H) 231.0956, found 231.0947.

**Withasomnine** (20). Raney Ni was washed 4 times with EtOH prior to use. A portion of the slurry was added to a solution of 25 (8.1 mg, 0.04 mmol) in EtOH (5 mL) and the reaction mixture was stirred at r.t. for 2 h. Then, the mixture was filtered through a pad of Celite, and the pad was washed with methanol. The combined organic fractions were concentrated under reduced pressure. The residue was purified by silica gel chromatography and elution with CH<sub>2</sub>Cl<sub>2</sub>/MeOH (100:0 to 95:5) gave withasomnine (20) (6.2 mg, 95%) as a yellowish oil. TLC R<sub>f</sub> 0.55 (95:5 CH<sub>2</sub>Cl<sub>2</sub>/MeOH). <sup>1</sup>H-NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  7.82 (s, 1H), 7.45 (dd, *J* = 8.1, 0.9 Hz, 2H), 7.38 – 7.34 (m, 2H), 7.19 (t, *J* = 7.4 Hz, 1H), 4.18 (t, *J* = 7.3 Hz, 2H), 3.10 (t, *J* = 7.3 Hz, 2H), 2.73 – 2.66 (m, 2H). <sup>13</sup>C-NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  142.6, 140.9, 133.4, 128.8, 125.6, 125.0, 115.3, 47.6, 26.4, 23.9. Spectroscopic data identical to the reported in literature.<sup>29</sup>

# H. NMR Data of Natural and Synthetic 19.

 Table 2. NMR data of natural and synthetic 19



	Natural 18	<b>3</b> <sup>29</sup>	Trauner's Synth	etic 18 <sup>30</sup>	Synthetic 18		
Position	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	
2	6.82 bs	147.0	6.84 bs	147.0	6.85 bs	147.1	
3	4.05 bs	61.1	4.00 bs	61.0	3.99 bs	60.9	
3a	3.68 m	71.4	3.72 – 3.64 m	71.2	3.72 – 3.65 m	71.2	
4	α 2.00 m β 1.56 m	31.4	α 2.03 – 1.95 m β 1.59 – 1.55 m	31.2	α 2.03 – 1.95 m β 1.65 – 1.54 m	31.2	
5	1.70 m	23.9	1.74 – 1.67 m	23.7	1.76 – 1.67 m	23.7	
6	3.69 m 3.17 m	53.6	3.72 – 3.64 m 3.23 – 3.16 m	53.5	3.72 – 3.65 m 3.23 – 3.17 m	53.5	
1'		140.5		140.3		140.3	
2', 6' 3', 5' 4'	} 7.34 – 7.26 m	127.3 129.0 127.4	} 7.36 – 7.21 m	127.1 128.9 127.3	<pre>7.33 - 7.29 m 7.26 - 7.21 m</pre>	127.2 128.9 127.3	

# I. NMR Data of Natural and Synthetic 20.

 Table 3. NMR data of natural and synthetic 20



	Natural 19	<b>)</b> <sup>29</sup>	Odom's Synthe	tic 18 <sup>31</sup>	Synthetic 19		
Position	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	<sup>1</sup> H-NMR	<sup>13</sup> C-NMR	
2	7.73 bs	141.0	7.79 s	140.9	7.82 s	140.9	
3		115.4		115.3		115.3	
3a		142.7		142.6		142.6	
4	3.07 t	26.5	3.08 t	26.4	3.10 t	26.4	
5	2.67 m	23.9	2.70 – 2.64 m	23.8	2.73 – 2.66 m	23.9	
6	4.13 t	47.6	4.16 t	47.6	4.18 t	47.6	
1'		133.5		133.4		133.4	
2', 6' 3', 5'	7.13 - 7.43	125.1 128.9	7.16 tt 7.33 d	125.0 128.8	7.19 t 7.38 – 7.34 m	125.0 128.8	
4'	)	125.7	7.44 – 7.42 m	125.6	7.45 dd	125.6	
# J. Synthesis of Azetidine, Azepane and Azocane Quasidimer Structures.



**Figure SI 4.** Proposed quasidimer structures from the 4-, 7- and 8-membered ring substrates (entries 2, 5 and 6 in Table 2):



(2*E*)-4-(But-3-enyl)-3,6-bis(methylthio)-1,2,4,5-tetraazabicyclo[6.2.0]deca-2,5-diene (proposed structure). Following the general procedure **B** and starting from 2c (56.0 mg, 0.33 mmol), elution with hexane/EtOAc (80:20 to 70:30) gave the entitled compound as a yellowish oil (29.3 mg, 63%). TLC R<sub>f</sub> 0.37 (75:25 hexane/EtOAc). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.92 – 5.82 (m, 1H), 5.13 – 5.01 (m, 2H), 3.95 (ddd, *J* = 13.9, 8.3, 5.9 Hz, 1H), 3.79 (ddd, *J* = 13.9, 8.2, 7.1 Hz, 1H), 2.69 – 2.59 (m, 1H), 2.58 – 2.47 (m, 3H), 2.28 (s, 3H), 2.21 – 2.09 (m, 5H), 1.92 – 1.81 (m, 2H), 1.64 (dtd, *J* = 14.3, 8.3, 6.0 Hz, 1H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.9, 150.3, 137.4, 116.1, 64.9, 55.3, 50.3, 42.1, 33.3, 32.1, 14.3, 13.7. FTIR (neat film) 3074, 2927, 2832, 1640, 1563, 1433, 1285, 1055 cm<sup>-1</sup>. **HRMS** (ESI) m/z: Calcd for C<sub>12</sub>H<sub>21</sub>N<sub>4</sub>S<sub>2</sub> (M+H) 285.1212, found 285.1208.



(3Z,6*E*)-5-(Hept-6-enyl)-2,7-bis(methylthio)-5,8,8a,9,10,11,12,13-octahydroazepino-[1,2-g][1,2,3,4,6,7]hexazecine (proposed structure). Following the general procedure **B** and starting from 2e (105.4 mg, 0.50 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/TBME (90:10 to 60:40) gave the monomer 3e (23.7 mg, 26%, characterized above), and the entitled compound (21.6 mg, 22%) as yellowish oils. TLC R<sub>f</sub> 0.94 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/TBME). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>) δ 5.79 (ddt, J = 16.9, 10.2, 6.7 Hz, 1H), 5.13 – 4.90 (m, 2H), 3.88 (t, J = 7.0 Hz, 2H), 2.75 (dt, J = 12.0, 7.8 Hz, 1H), 2.70 – 2.60 (m, 2H), 2.36 (dd, J = 15.4, 9.1 Hz, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.12 (dd, J = 15.4, 13.5 Hz, 1H), 2.07 – 2.01 (m, 2H), 1.98 – 1.93 (m, 1H), 1.92 – 1.83 (m, 1H), 1.53 – 1.46 (m, 1H), 1.46 – 1.37 (m, 5H), 1.34 (ddd, J = 10.1, 6.0, 2.4 Hz, 1H), 1.22 – 1.11 (m, 1H), 0.86 – 0.70 (m, 4H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>) δ 165.8, 149.7, 139.6, 114.9, 68.7, 55.8, 53.1, 43.0, 34.6, 32.9, 29.7, 29.5, 28.9, 27.7, 26.8, 26.2, 14.3, 13.8. FTIR (neat film) 3075, 2929, 2858, 1641, 1564, 1375, 1283, 1056 cm<sup>-1</sup>. HRMS (ESI) m/z: Calcd for C<sub>18</sub>H<sub>33</sub>N<sub>6</sub>S<sub>2</sub> (M+H) 397.2208, found 397.2214.



## (3Z,6E)-2,7-bis(Methylthio)-5-(oct-7-enyl)-8,8a,9,10,11,12,13,14-octahydro-5*H*-azocino-

[1,2-g][1,2,3,4,6,7]hexazecine (proposed structure). Following the general procedure **B** and starting from 2g (68.4 mg, 0.30 mmol), elution with CH<sub>2</sub>Cl<sub>2</sub>/THF (95:5 to 85:15) gave the entitled compound as a yellowish oil (19.4 mg, 30%). TLC R<sub>f</sub> 0.94 (70:30 CH<sub>2</sub>Cl<sub>2</sub>/THF). <sup>1</sup>H-NMR (600 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  5.84 – 5.71 (m, 1H), 5.10 – 4.92 (m, 2H), 3.90 (t, *J* = 7.0 Hz, 2H), 2.82 (dt, *J* = 12.0, 7.8 Hz, 1H), 2.78 – 2.66 (m, 1H), 2.41 (dd, *J* = 15.4, 9.1 Hz, 1H), 2.30 (s, 3H), 2.27 (s, 3H), 2.17 (dd, *J* = 15.4, 13.6 Hz, 1H), 2.05 – 1.90 (m, 3H), 1.95 – 1.87 (m, 2H), 1.52 – 1.19 (m, 10H), 0.95 – 0.76 (m, 6H). <sup>13</sup>C-NMR (151 MHz, C<sub>6</sub>D<sub>6</sub>)  $\delta$  165.8, 149.7, 139.6, 114.9, 68.9, 56.0, 53.2, 43.1, 34.6, 33.3, 29.8, 29.7, 29.5, 29.4, 29.1, 28.1, 26.8, 26.7, 14.3, 13.8. FTIR (neat film) 3073, 2927, 2855, 1639, 1562, 1433, 1282, 1148, 1054 cm<sup>-1</sup>. HRMS (ESI) *m/z*: Calcd for C<sub>20</sub>H<sub>37</sub>N<sub>6</sub>S<sub>2</sub> (M+H) 425.2521, found 425.2532.

# K. References and Notes.

- 1. C. F. Purchase and A. D. White, *Synth. Commun.*, 1996, **26**, 2687-2694.
- 2. In general, reactions proceed cleanly from starting material to product under the optimized reaction conditions. The moderate yields are due to incomplete conversions, but longer irradiation times were not beneficial and provided a higher extent of the corresponding thiopyrazolone by-products **4**.
- 3. (a) Synthesized as a colorless oil (827.7 mg, 99%) by  $LiAlH_4$  reduction of (*Z*)-ethyl 5-cyclopropylpent-4enoate. Spectroscopic data identical to the reported in literature; (b) C. Paolucci and P. Righi, *Tetrahedron*, 2007, **63**, 12763-12768.
- 4. (a) Z. Cai, N. Yongpruksa and M. Harmata, *Org. Lett.*, 2012, **14**, 1661-1663; (b) Synthesized as described in literature.
- (a) Synthesized as a colorless oil (1.119 g, 92%) by LiAlH<sub>4</sub> reduction of methyl 5-methylhex-4-enoate in THF. Spectroscopic data identical to the reported in literature; (b) E. J. Corey, H. Cheng, C. H. Baker, S. P. T. Matsuda, D. Li and X. Song, J. Am. Chem. Soc., 1997, 119, 1277-1288.
- 6. P. M. Tadross, P. Bugga and B. M. Stoltz, Org. Biomol. Chem. , 2011, 5354-5357.
- (a) M. R. Ashcroft, P. Bougeard, A. Bury, C. J. Cooksey, M. D. Johnson, J. M. Hungerford and G. M. Lampman, *J. Org. Chem.*, 1984, 49, 1751-1761; (b) K. A. McManus and D. R. Arnold, *Can. J. Chem.*, 1995, 73, 2158-2169.
- 8. (a) Synthesized as described in literature. Spectroscopic data identical to the reported in literature; (b) S. Raghavan and V. Sudheerbabu, *Chemistry A European Journal*, 2011, **17**, 8487 8494.
- 9. F. C. Courchay, T. W. Baughman and K. B. Wagener, J. Organomet. Chem., 2006, 691, 585-594.
- 10. Synthesized as a colorless oil (160.0 mg, quant.) by  $LiAlH_4$  reduction of methyl 2-(2-methylenecyclopentyl)acetate. Spectroscopic data identical to the reported in literature.
- 11. R. G. Salomon, S. Ghosh, M. G. Zagorski and M. Reitz, J. Org. Chem., 1982, 47, 829-836.
- 12. L. Wang, K. Thai and M. Gravel, Org. Lett., 2009, 11, 891-893.
- 13. S. H. Park, H. J. Kang, S. Ko, S. Park and S. Chang, *Tetrahedron: Asymmetry*, 2001, **12**, 2621-2624
- 14. (*R*)-methyl 1-allylpiperidine-2-carboxylate was synthesized using the following procedure: allyl bromide (3.4 mL, 38.7 mmol) was added to a mixture of (*R*)-methyl piperidine-2-carboxylate hydrochloride (3.477 g, 19.4 mmol) and Et<sub>3</sub>N (10.8 mL, 77.4 mmol) in THF/DMF (95:5, 40 mL) at r.t. After stirring for 20 h at r.t., the reaction mixture was evaporated under reduced pressure. The residue was purified by silica gel chromatography and elution with hexane/EtOAc (85:15 to 75:25) gave the entitled product (3.325 g, 94%) as a colorless oil. <sup>1</sup>H NMR (600 MHz, CDCl<sub>3</sub>)  $\delta$  5.87 (dddd, *J* = 17.1, 10.1, 7.9, 5.6 Hz, 1H), 5.18 5.09 (m, 2H), 3.71 (s, 3H), 3.26 3.19 (m, 1H), 3.08 2.99 (m, 2H), 2.91 (dd, *J* = 13.5, 7.9 Hz, 1H), 2.18 2.10 (m, 1H), 1.87 1.79 (m, 1H), 1.77 1.69 (m, 1H), 1.68 1.57 (m, 3H), 1.32 (tdd, *J* = 10.8, 8.6, 4.2 Hz, 1H). <sup>13</sup>C NMR (151 MHz, CDCl<sub>3</sub>)  $\delta$  174.2, 134.6, 118.1, 65.0, 59.7, 51.6, 50.9, 29.7, 25.2, 22.7. (*R*)-Methyl piperidine-2-carboxylate hydrochloride precursor was synthesized from (*R*)-Piperidine-2-carboxylate added to a filterature for the *S*-enantiomer.
- 15. P. Zajdel, G. Nomezine, N. Masurier, M. Amblard, M. Pawłowski, J. Martinez and G. Subra, *Chemistry A European Journal*, 2010, **16**, 7547-7553.
- 16. The desired product was obtained with traces of the corresponding 1-substituted tetrazole regioisomer as an impurity.

- 17. C. Pasquier, S. Naili, L. Pelinski, J. Brocard, A. Mortreux and F. Agbossou, *Tetrahedron: Asymmetry*, 1998, **9**, 193-196.
- 18. K. C. Nicolaou, D. A. Claremon and W. E. Barnette, J. Am. Chem. Soc., 1980, **102**, 6611-6612.
- 19. Synthesized as a colorless oil (525.3 mg, 99%) by  $LiAlH_4$  reduction of methyl (*E/Z*)-2-(2-(methoxymethylene)cyclopentyl)acetate. Spectroscopic data identical to the reported in literature.
- 20. D. A. Frey, S. H. Krishna Reddy and K. D. Moeller, J. Org. Chem., 1999, 64, 2805-2813.
- (a) Synthesized as a colorless oil (762.3 mg, 94%) by LiAlH<sub>4</sub> reduction of methyl 4,4-dimethoxybutyrate as described in literature. Spectroscopic data identical to the reported in literature; (b) J. R. Hazen, *J. Org. Chem.*, 1970, **35**, 973-978; (c) R. W. Hoffmann and I. Münster, *Liebigs Annalen*, 1997, **1997**, 1143-1150.
- 22. (a) F. F. Blicke and B. A. Brown, *J. Org. Chem.*, 1961, **26**, 3685-3691; (b) H. M. Deutsch, X. Ye, Q. Shi, Z. Liu and M. M. Schweri, *European Journal of Medicinal Chemistry*, 2001, **36**, 303-311.
- 23. A. Padwa, S. Nahm and E. Sato, J. Org. Chem., 1978, 43, 1664-1671.
- 24. J.-G. Roveda, C. Clavette, A. D. Hunt, S. I. Gorelsky, C. J. Whipp and A. M. Beauchemin, *J. Am. Chem. Soc.*, 2009, **131**, 8740-8741.
- 25. (a) Spectroscopic data identical to the reported in literature; (b) US Pat., US 2006/0205955 A1, 2006.
- 26. T. Zheng, R. S. Narayan, J. M. Schomaker and B. Borhan, J. Am. Chem. Soc., 2005, 127, 6946-6947.
- (a) Synthesized as a colorless oil (4.20 g, 99%) by LiAlH<sub>4</sub> reduction of (*E*)-5-phenylpent-4-enoic acid. Spectroscopic data identical to the reported in literature; (b) M. Abul Hashem and P. Weyerstahl, *Tetrahedron*, 1984, 40, 2003-2009; (c) S. E. Denmark and M. T. Burk, *Org. Lett.*, 2012, 14, 256-259.
- 28. G. Liu and S. S. Stahl, J. Am. Chem. Soc., 2007, 129, 6328-6335.
- 29. S. A. Adesanya, R. Nia, C. Fontaine and M. Païs, *Phytochemistry*, 1994, **35**, 1053 -1055.
- 30. M. Pangerl, C. C. Hughes and D. Trauner, *Tetrahedron*, 2010, **66**, 6626-6631.
- 31. S. Majumder, K. R. Gipson, R. J. Staples and A. L. Odom, *Adv. Synth. Catal.*, 2009, **351**, 2013-2023.

# L. <sup>1</sup>H and <sup>13</sup>C-NMR Spectra.

### dp-1-097f2530

\* plaquerd dp-1-097f2530 (10 1) CDCl3 24.0C November\_23,2010\_18:59:57 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* :Proton CDCl3 /opt/users/plaquerd plaquerd 18



dp-2-080f2529 .\* plaquerd dp-2-080f2529 (10 1) CDCl3 24.0C December\_17,2010\_12:33:24 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* :Proton CDCl3 /opt/users/plaquerd plaquerd 18



								· · ·	· · ·			· ·						· · ·	· ·		· ·	
200	19	0	180	170	160	150	140	130	120	110	100 f1 (ppn	90 n)	80	70	6	0	50	40	30	20	10	0

#### Group Gin DP-III-153-f4652

\* plaquerd DP-III-153-f4652 (10 1) C6D6 24.0C July\_21,2011\_00:03:57 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 17



1									· ·											· ·
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90 I)	80	70	60	50	40	30	20	10	0



Proton .\* plaquerd dp-1-109f2022 (1 1) CDCl3 24.0C August\_31,2010\_16:24:07 Bruker AVIII 500.26 MHz Adspice zg30 1H \*.



### Group Gin DP-II-253-f1720

\* plaquerd DP-II-253-f1720 (10 1) C6D6 24.0C February\_15,2011\_18:20:53 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 22





· · · ·				- · ·	- I - I				- I - I											
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90	80	70	60	50	40	30	20	10	0





		1 1	1							1											·
20	0 :	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90	80	70	60	50	40	30	20	10	0



Group Gin Pla-D-2012-050-f3641

\* plaquerd Pla-D-2012-050-f3641 (10 1) C6D6 24.0C April\_06,2012\_00:26:25 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm Proton C6D6 /opt/users/plaquerd plaquerd 28



### Group Gin Pla-D-2012-067-f814

\* plaquerd Pla-D-2012-067-f814 (10 1) C6D6 24.0C April\_19,2012\_19:24:56 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm Proton C6D6 /opt/users/plaquerd plaquerd 31





#### dp-1-113f1719

\* plaquerd dp-1-113f1719 (10 1) CDCl3 24.0C November\_24,2010\_20:31:45 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* Proton CDCl3 /opt/users/plaquerd plaquerd 40



											· ·	· · ·			· · ·	· · ·				· ·
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90 )	80	70	60	50	40	30	20	10	0

dp-2-023f5760 .\* plaquerd dp-2-023f5760 (10 1) CDCl3 24.0C November\_24,2010\_17:59:36 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* :Proton CDCl3 /opt/users/plaquerd plaquerd 38



											· ·			· ·	· ·	· · ·			1	· ·
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90	80	70	60	50	40	30	20	10	0

dp-1-117f1618 .\* plaquerd dp-1-117f1618 (10 1) CDCl3 24.0C November\_24,2010\_19:15:39 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* :Proton CDCl3 /opt/users/plaquerd plaquerd 39



200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90 )	80	70	60	50	40	30	20	10	0



									1						1					
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90	80	70	60	50	40	30	20	10	0



dp-2-033f2127

.\* plaquerd dp-2-033f2127 (10 1) CDCl3 24.0C October\_28,2010\_13:49:23 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton CDCl3 /opt/users/plaquerd plaquerd 22



### Group Gin DP-III-147-f914

\* plaquerd DP-III-147-f914 (10 1) C6D6 24.0C July\_20,2011\_17:32:05 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 14









Group Gin DP-II-105-f2832

\* plaquerd DP-II-105-f2832 (10 1) C6D6 24.0C January\_27,2011\_16:44:30 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 27



110

90

#### Gin Lab DP-III-023-f2631

\* plaquerd DP-III-023-f2631 (10 1) C6D6 24.0C March\_24,2011\_08:54:00 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 32





200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90 1)	80	70	) 60	50	40	30	20	10	0





dp-2-034f7989

\* plaquerd dp-2-034f7989 (10 1) CDCl3 24.0C October\_28,2010\_14:51:19 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton CDCl3 /opt/users/plaquerd plaquerd 23



dp-2-034f92104

\* plaquerd dp-2-034f92104 (10 1) CDCl3 24.0C October\_28,2010\_16:16:02 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton CDCl3 /opt/users/plaquerd plaquerd 24



Proton .\* plaquerd dp-1-112f2426 (1 1) CDCl3 24.0C September\_02,2010\_16:04:31 Bruker AVIII 500.26 MHz Adspice zg30 1H \*.





110 100 f1 (ppm) 


Group Gin Pla-D-2012-023-f5359

\* plaquerd Pla-D-2012-023-f5359 (10 1) C6D6 24.0C March\_06,2012\_08:59:16 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm Proton C6D6 /opt/users/plaquerd plaquerd 24



Group Gin

\* plaquerd Pla-D-2012-026-f6770 (10 1) C6D6 24.0C March\_07,2012\_19:02:59 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm Proton C6D6 /opt/users/plaquerd plaquerd 16



200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90 I)	80	70	60	50	40	30	20	10	0





dp-2-037f102104 .\* plaquerd dp-2-037f102104 (10 1) CDCl3 24.0C November\_05,2010\_10:35:26 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton CDCl3 /opt/users/plaquerd plaquerd 19



## (83% estimated purity by NMR)



. Г		1																				
20	0	190	18	30	170	160	150	140	130	120	110	100 f1 (ppm	90 1)	80	70	60	50	40	30	20	10	0



## Group Gin DP-III-161-f2734

\* plaquerd DP-III-161-f2734 (10 1) C6D6 24.0C July\_21,2011\_21:11:03 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 31



															1					
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90	80	70	60	50	40	30	20	10	0

f1 (ppm)

Group Gin DP-II-104-f2529

\* plaquerd DP-II-104-f2529re (10 1) C6D6 24.0C January\_26,2011\_20:03:20 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* Proton C6D6 /opt/users/plaquerd plaquerd 31







Group Gin DP-II-271-f4651 .\* plaquerd DP-II-271-f4651 (10 1) C6D6 24.0C February\_24,2011\_15:15:34 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 31







																				٦
200	190	180	170	160	150	140	130	120	110	100	90	80	70	60	50	40	30	20	10	0
										f1 (ppm)										





· · · ·	· · ·				· ·			- · ·	1					- · ·	· · ·					
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90	80	70	60	50	40	30	20	10	0

dp-2-082f2531 \* plaquerd dp-2-082f2531 (10 1) C6D6 24.0C December\_21,2010\_17:25:13 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 25



0.5

0.0











Group Gin Pla-D-2012-060-f1520-CDCl3 .\* plaquerd Pla-D-2012-060-f1520-CDCl3 (11 1) CDCl3 24.0C April\_21,2012\_15:37:57 Bruker AVIII 600MHz DCH cryo ZRC 2134: zgpg30 : 13C 1 :Carbon CDCl3 /opt/users/plaquerd plaquerd 29









200

190

180

170

160

150

140

130

120

110

100 f1 (ppm) 90

80

70

60

50

40

30

20

10

0

Group Gin DP-III-155-f7681 .\* plaquerd DP-III-155-f7681 (10 1) C6D6 24.0C July\_22,2011\_02:23:24 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 33 MeS н (19:1 dr) 94.2-I 5.8 🕂 9.5 8.5 8.0 7.5 7.0 6.5 5.0 f1 (ppm) 4.0 3.5 3.0 2.5 2.0 0.5 0.0 9.0 6.0 5.5 4.5 1.5 1.0 Group Gin DP-III-155-f7681 .\* plaquerd DP-III-155-f7681 (11 1) C6D6 24.0C uly\_22,2011\_02:25:14 Bruker AVIII 600MHz DCH cryo ZRC 2134: zgpg30 : 13C 130.000 ppm; :Carbon C6D6 /opt/users/plaquerd plaquerd 33







200

190

180

170

160

150

140

130

120

110

100 f1 (ppm) 90

80

70

60

50

40

30

20

10

0

Н MeS Ĥ (99% estimated purity by NMR) λı, 98.7H 1.3 🛓 10.0 9.5 8.0 7.5 7.0 5.0 f1 (ppm) 4.0 3.5 3.0 2.5 0.5 0.0 9.0 8.5 6.5 6.0 5.5 4.5 2.0 1.5 1.0 Group Gin DP-III-43-f4246 .\* plaquerd DP-III-43-f4246 (11 1) C6D6 24.0C April\_07,2011\_16:30:53 Bruker AVIII 600MHz DCH cryo ZRC 2134: zgpg30 : 13C 130.000 ppm; :Carbon C6D6 /opt/users/plaquerd plaquerd 28





Group Gin DP-III-31-f3036 .\* plaquerd DP-III-31-f3036 (10 1) C6D6 24.0C March\_31,2011\_16:28:22 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 15



0.5

1.0

0.0

dp-2-086f2528 \* plaquerd dp-2-086f2528 (10 1) C6D6 24.0C December\_22,2010\_02:38:13 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 28 MeS Мe MeÒ (18:2 dr) 89.6~

9.5

9.0

8.5

8.0

7.5

7.0

6.5

6.0

5.5

10.0

dp-2-086f2528 .\* plaquerd dp-2-086f2528 (11 1) C6D6 24.0C December\_22,2010\_02:40:02 Bruker AVIII 600MHz DCH cryo ZRC 2134: zgpg30 : 13C 120.000 p :Carbon C6D6 /opt/users/plaquerd plaquerd 28

5.0 f1 (ppm)

4.5

4.0

3.5

3.0

2.5

2.0

1.5





\* plaquerd DP-III-11-Z-f2936 (10 1) C6D6 24.0C March\_20,2011\_00:07:21 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 28







\* plaquerd DP-II-247-f1723 (10 1) CDCl3 24.0C February\_11,2011\_18:02:29 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \* Proton CDCl3 /opt/users/plaquerd plaquerd 29



Group Gin Pla-D-2012-028-f3435 .\* plaquerd Pla-D-2012-028-f3435 (10 1) C6D6 24.0C March\_08,2012\_17:38:19 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 28

С N٠ EtÓ

(96% estimated purity by NMR)






			1

1 1

· · · ·															1			1	· · · ·	
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm)	90	80	70	60	50	40	30	20	10	0









Group Gin Pla-D-2012-001-f3139 .\* plaquerd Pla-D-2012-001-f3139 (10 1) CDCl3 24.0C January\_24,2012\_14:31:44 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton CDCl3 /opt/users/plaquerd plaquerd 40





Group Gin DP-III-55-f4954

\* plaquerd DP-III-55-f4954 (10 1) C6D6 24.0C April\_27,2011\_16:07:36 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton C6D6 /opt/users/plaquerd plaquerd 29



									· · · ·	· · ·										· ·
200	190	180	170	160	150	140	130	120	110	100 f1 (ppm	90 )	80	70	60	50	40	30	20	10	0

Group Gin DP-III-89-f3038 .\* plaquerd DP-III-89-f3038 (10 1) C6D6 24.0C May\_19,2011\_14:03:06 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton C6D6 /opt/users/plaquerd plaquerd 34 MeS Н 6.5 10.0 9.5 . 9.0 .5 8.0 7.5 7.0 6.0 5.5 5.0 f1 (ppm) 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0 Group Gin DP-III-89-f3038 .\* plaquerd DP-III-89-f3038 (11 1) C6D6 24.0C May\_19,2011\_14:05:04 Bruker AVIII 600MHz DCH cryo ZRC 2134: zgpg30 : 13C 130.000 ppm; :Carbon C6D6 /opt/users/plaquerd plaquerd 34 200 190 180 170 160 150 140 130 120 110 100 f1 (ppm) 90 80 70 60 50 40 30 20 10

## Group Gin DP-III-113-f1926

\* plaquerd DP-III-113-f1926 (10 1) CDCl3 24.0C June\_30,2011\_20:09:37 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. Proton CDCl3 /opt/users/plaquerd plaquerd 23



f1 (ppm) 





Group Gin DP-III-81-f5269

\* plaquerd DP-III-81-f5269 (10 1) CDCl3 24.0C May\_19,2011\_20:12:36 Bruker AVIII 600MHz DCH cryo ZRC 2134: zg30 : 1H 6.175 ppm \*. :Proton CDCl3 /opt/users/plaquerd plaquerd 36











## M. NOESY, COSY, HSQC and HMBC Spectra of Selected Compounds.



































